Anti-TAU Antibodies and Methods of Use

Anti-Tau antibodies with high affinity for human Tau are developed to target and modulate Tau protein levels, addressing the specificity and effectiveness issues of current therapies, thereby reducing neurodegeneration and preserving cognitive function.

JP7594574B2Active Publication Date: 2024-12-04GENENTECH INC +1
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2022196074
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2016-12-07
Filing Date
2022-12-08
Publication Date
2024-12-04
Estimated Expiration
2037-12-06

AI Technical Summary

Technical Problem

Current therapeutic approaches for neurodegenerative disorders associated with Tau protein, such as Alzheimer's disease, lack specificity and effectiveness in targeting pathological Tau conformers, leading to a need for more targeted therapeutic agents.

Method used

Development of anti-Tau antibodies with high affinity for human Tau, capable of binding to monomeric, oligomeric, unphosphorylated, and phosphorylated forms of Tau, including monoclonal, human, humanized, or chimeric antibodies, with specific variable regions and mutations, to target and modulate Tau protein levels.

Benefits of technology

The anti-Tau antibodies effectively bind to Tau proteins, potentially reducing their levels and slowing down neurodegenerative processes, thereby preserving cognitive memory capacity and slowing memory loss in individuals with Tau-related diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007594574000068
    Figure 0007594574000068
  • Figure 0007594574000069
    Figure 0007594574000069
  • Figure 0007594574000070
    Figure 0007594574000070
Patent Text Reader

Abstract

Anti-Tau antibodies and methods of use thereof are provided. [Solution] Provided are an isolated antibody that binds to human Tau, the antibody comprising HVR-H1, HVR-H2, and HVR-H3 that comprise specific amino acid sequences, and use of the isolated antibody for manufacturing a pharmaceutical for treating a Tau protein-associated disease in an individual.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of priority to U.S. Provisional Patent Application No. 62 / 431,180, filed December 7, 2016, which is incorporated herein by reference in its entirety for all purposes.

[0002] The present invention relates to anti-Tau antibodies and methods of use thereof. [Background technology]

[0003] Neurofibrillary tangles and neuropil threads (NTs) are major neuropathological features of Alzheimer's disease (AD). NTs are composed of microtubule-associated Tau protein that has undergone post-translational modifications, including phosphorylation, and develop through the aggregation of hyperphosphorylated Tau conformers. AD shares this pathology with many neurodegenerative tauopathies, particularly certain types of frontotemporal dementia (FTD). Tau protein appears to be a key player in cognitive decline in AD and related neurodegenerative tauopathies.

[0004] There are few therapeutic approaches targeting Tau protein, mainly including inhibitors of kinases that are thought to increase Tau phosphorylation to pathological levels, and compounds that block the cytoplasmic aggregation of hyperphosphorylated Tau protein. These approaches suffer from various shortcomings in specificity and efficacy. There is a need for additional therapeutic agents that target pathological protein conformers that are known or suspected to cause neurodegenerative disorders. Summary of the Invention

[0005] The present disclosure provides anti-Tau antibodies and methods of use thereof. In some embodiments, antibodies are provided that have high affinity for human and cynomolgus monkey Tau. In some embodiments, the antibodies have an affinity for human Tau of less than 1 nM, or less than 0.5 nM, or less than 0.3 nM, as measured, for example, by surface plasmon resonance.

[0006] In some embodiments, an isolated antibody that binds to human Tau is provided, wherein the antibody binds to monomeric Tau, oligomeric Tau, unphosphorylated Tau, and phosphorylated Tau. In some embodiments, the antibody binds to an epitope within amino acids 2-24 of mature human Tau. In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the antibody is a human, humanized, or chimeric antibody. In some embodiments, the antibody is an antibody fragment that binds to human Tau. In some embodiments, human Tau comprises the sequence of SEQ ID NO:2.

[0007] In some embodiments, the antibody comprises HVR-H1 comprising the amino acid sequence of SEQ ID NO: 605, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 606, and HVR-H3 comprising the amino acid sequence of SEQ ID NO: 607.

[0008] In some embodiments, the antibody comprises HVR-L1 comprising the amino acid sequence of SEQ ID NO: 608, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 609, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 610.

[0009] In some embodiments, the antibody comprises HVR-H1 comprising the amino acid sequence of SEQ ID NO: 605, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 606, HVR-H3 comprising the amino acid sequence of SEQ ID NO: 607, HVR-L1 comprising the amino acid sequence of SEQ ID NO: 608, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 609, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 610.

[0010] In some embodiments, the antibody a) a heavy chain variable region (VH) comprising a sequence at least 95% identical to SEQ ID NO: 603; b) a light chain variable region (VL) comprising a sequence at least 95% identical to SEQ ID NO: 604; c) VH as in (a) and VL as in (b); d) a heavy chain variable region (VH) comprising a sequence at least 95% identical to SEQ ID NO: 614; e) a light chain variable region (VL) comprising a sequence at least 95% identical to SEQ ID NO: 615; f) VH as in (d) and VL as in (e); g) a heavy chain variable region (VH) comprising a sequence at least 95% identical to SEQ ID NO: 619; h) a light chain variable region (VL) comprising a sequence at least 95% identical to SEQ ID NO: 620; i) Contains a VH as in (g) and a VL as in (h).

[0011] In some embodiments, the antibody a) a heavy chain variable region (VH) comprising SEQ ID NO: 603; b) a light chain variable region (VL) comprising SEQ ID NO: 604; c) VH as in (a) and VL as in (b); d) a heavy chain variable region (VH) comprising the sequence of SEQ ID NO: 614; e) a light chain variable region (VL) comprising the sequence of SEQ ID NO: 615; f) VH as in (d) and VL as in (e); g) a heavy chain variable region (VH) comprising the sequence of SEQ ID NO: 619; h) a light chain variable region (VL) comprising the sequence of SEQ ID NO: 620; i) Contains a VH as in (g) and a VL as in (h).

[0012] In some embodiments, the antibody comprises a heavy chain variable region comprising a sequence selected from SEQ ID NOs: 603, 614, and 619, and a light chain variable region comprising a sequence selected from SEQ ID NOs: 604, 615, and 620. In some embodiments, the antibody comprises a heavy chain variable region comprising a sequence selected from SEQ ID NOs: 340, 603, 614, and 619, and a light chain variable region comprising a sequence selected from SEQ ID NOs: 604, 615, and 620. In some embodiments, the antibody comprises a heavy chain variable region comprising a sequence selected from SEQ ID NOs: 603, 614, and 619, and a light chain variable region comprising a sequence selected from SEQ ID NOs: 341, 604, 615, and 620.

[0013] In some embodiments, the antibody comprises (a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 603 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 604; (b) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 614 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 615; or (c) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 619 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 620.

[0014] In some embodiments, the antibody comprises (a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 611 or SEQ ID NO: 612, and a light chain comprising the amino acid sequence of SEQ ID NO: 613; (b) a heavy chain comprising the amino acid sequence of SEQ ID NO: 616 or SEQ ID NO: 617, and a light chain comprising the amino acid sequence of SEQ ID NO: 618; or (c) a heavy chain comprising the amino acid sequence of SEQ ID NO: 621 or SEQ ID NO: 622, and a light chain comprising the amino acid sequence of SEQ ID NO: 623.

[0015] In some embodiments, an isolated antibody that binds to human Tau is provided, the isolated antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:611 or SEQ ID NO:612, and a light chain comprising the amino acid sequence of SEQ ID NO:613. In some embodiments, an isolated antibody that binds to human Tau is provided, the isolated antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:611, and a light chain comprising the amino acid sequence of SEQ ID NO:613. In some embodiments, an isolated antibody that binds to human Tau is provided, the isolated antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:612, and a light chain comprising the amino acid sequence of SEQ ID NO:613. In some embodiments, an isolated antibody that binds to human Tau is provided, the isolated antibody comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO:611 or SEQ ID NO:612, and a light chain consisting of the amino acid sequence of SEQ ID NO:613. In some embodiments, an isolated antibody that binds to human Tau is provided, the isolated antibody comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO:611, and a light chain consisting of the amino acid sequence of SEQ ID NO:613. In some embodiments, an isolated antibody that binds to human Tau is provided, the isolated antibody comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO:612 and a light chain consisting of the amino acid sequence of SEQ ID NO:613.

[0016] In some embodiments, an isolated antibody that binds to human Tau is provided, the isolated antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 616 or 617, and a light chain comprising the amino acid sequence of SEQ ID NO: 618. In some embodiments, an isolated antibody that binds to human Tau is provided, the isolated antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 616, and a light chain comprising the amino acid sequence of SEQ ID NO: 618. In some embodiments, an isolated antibody that binds to human Tau is provided, the isolated antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 617, and a light chain comprising the amino acid sequence of SEQ ID NO: 618. In some embodiments, an isolated antibody that binds to human Tau is provided, the isolated antibody comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 616 or SEQ ID NO: 617, and a light chain consisting of the amino acid sequence of SEQ ID NO: 618. In some embodiments, an isolated antibody that binds to human Tau is provided, the isolated antibody comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 616, and a light chain consisting of the amino acid sequence of SEQ ID NO: 618. In some embodiments, an isolated antibody that binds to human Tau is provided, the isolated antibody comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO:617 and a light chain consisting of the amino acid sequence of SEQ ID NO:618.

[0017] In some embodiments, an isolated antibody that binds to human Tau is provided, the isolated antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 621 or SEQ ID NO: 622, and a light chain comprising the amino acid sequence of SEQ ID NO: 623. In some embodiments, an isolated antibody that binds to human Tau is provided, the isolated antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 621, and a light chain comprising the amino acid sequence of SEQ ID NO: 623. In some embodiments, an isolated antibody that binds to human Tau is provided, the isolated antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 622, and a light chain comprising the amino acid sequence of SEQ ID NO: 623. In some embodiments, an isolated antibody that binds to human Tau is provided, the isolated antibody comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 621 or SEQ ID NO: 622, and a light chain consisting of the amino acid sequence of SEQ ID NO: 623. In some embodiments, an isolated antibody that binds to human Tau is provided, the isolated antibody comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 621, and a light chain consisting of the amino acid sequence of SEQ ID NO: 623. In some embodiments, an isolated antibody that binds to human Tau is provided, the isolated antibody comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO:622 and a light chain consisting of the amino acid sequence of SEQ ID NO:623.

[0018] In any of the embodiments described herein, the antibody may be an IgG1 or IgG4 antibody. In any of the embodiments described herein, the antibody may be an IgG4 antibody. In some such embodiments, the antibody comprises M252Y, S254T, and T256E mutations. In any of the embodiments described herein, the antibody may comprise an S228P mutation. In any of the embodiments described herein, the antibody may comprise S228P, M252Y, S254T, and T256E mutations. In any of the embodiments described herein, the antibody may be an IgG4 antibody comprising S228P, M252Y, S254T, and T256E mutations. In some embodiments, the antibody is an antibody fragment. In any of the embodiments described herein, the antibody may be an IgG4 antibody comprising S228P, M252Y, S254T, and T256E mutations and lacking the C-terminal lysine (des-K) of the heavy chain constant region. The C-terminal lysine of the heavy chain constant region may be removed, for example, during purification of the antibody or by recombinant engineering of the nucleic acid encoding the antibody, such that the C-terminal lysine is not encoded.

[0019] In some embodiments, an isolated antibody that binds to human Tau and has a K of less than 100 nM, less than 75 nM, less than 50 nM, less than 10 nM, less than 5 nM, or less than 1 nM for each of monomeric Tau, phosphorylated Tau, non-phosphorylated Tau, and oligomeric Tau. D In some embodiments, the antibody binds to cynomolgus monkey Tau. In some embodiments, the antibody binds to human monomeric Tau and / or cynomolgus monkey monomeric Tau with a K of less than 1 nM. D Combine with.

[0020] In some embodiments, an isolated nucleic acid is provided that encodes an antibody described herein. In some embodiments, a host cell is provided that comprises an isolated nucleic acid that encodes an antibody described herein. In some embodiments, a method of producing an antibody is provided, comprising culturing the host cell under conditions suitable for production of the antibody.

[0021] In some embodiments, an immunoconjugate is provided comprising an isolated antibody described herein and a therapeutic agent. In some embodiments, a labeled antibody is provided comprising an antibody described herein and a detectable label.

[0022] In some embodiments, a pharmaceutical composition is provided comprising an isolated antibody described herein and a pharmaceutically acceptable carrier.

[0023] In some embodiments, a method for treating a Tau protein-associated disease is provided, comprising administering an antibody described herein or a pharmaceutical composition comprising an antibody described herein to an individual having the Tau protein-associated disease. In some embodiments, the Tau protein-associated disease is a tauopathy. In some embodiments, the tauopathy is a neurodegenerative tauopathy. In some embodiments, the tauopathy is Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, Creutzfeldt-Jakob disease, drunkard pugilistica, Down syndrome, Gerstmann-Sträussler-Scheinker disease, inclusion body myositis, prion protein cerebral amyloid angiopathy, traumatic brain injury, Guam amyotrophic lateral sclerosis / parkinsonism dementia syndrome, non-Guam motor neuron disease with neurofibrillary tangles, argyrophilic grain dementia, and glaucoma. The tauopathy is selected from corticobasal degeneration, diffuse neurofibrillary tangle disease with calcifications, frontotemporal dementia, frontotemporal dementia with parkinsonism linked to chromosome 17, Hallervorden-Spatz disease, multiple system atrophy, Niemann-Pick disease type C, pallido-ponto-nigral degeneration, Pick's disease, progressive subcortical gliosis, progressive supranuclear palsy, subacute sclerosing panencephalitis, neurofibrillary tangle dementia, postencephalitic parkinsonism, and myotonic dystrophy. In some embodiments, the tauopathy is Alzheimer's disease or progressive supranuclear palsy. In some embodiments, the Tau protein-associated disease is selected from PART (primary age-related tauopathy), alteration-predominant dementia, subacute sclerosing panencephalopathy, chronic traumatic encephalopathy (CTE), white matter tauopathy with globular glial inclusions, Lewy body disease (LBD), mild cognitive impairment (MCI), glaucoma, familial British dementia, familial Danish dementia, Guadeloupean Parkinsonism, neurodegeneration with cerebral iron deposition, SLC9A6-associated intellectual disability, multiple sclerosis, HIV-associated dementia, senile cardiac amyloidosis, and Huntington's disease.

[0024] In some embodiments, methods are provided for preserving or increasing cognitive memory capacity or slowing memory loss in an individual, comprising administering an antibody described herein or a pharmaceutical composition comprising an antibody described herein.

[0025] In some embodiments, methods are provided for reducing the level of Tau protein, non-phosphorylated Tau protein, phosphorylated Tau protein, or hyperphosphorylated Tau protein in an individual, comprising administering an antibody described herein or a pharmaceutical composition comprising an antibody described herein.

[0026] In some embodiments, an isolated antibody described herein is provided for use as a pharmaceutical. In some embodiments, an isolated antibody described herein is provided for use in treating a tauopathy in an individual. In some embodiments, the tauopathy is a neurodegenerative tauopathy. In some embodiments, the tauopathy is Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, Creutzfeldt-Jakob disease, drunkard pugilistica, Down syndrome, Gerstmann-Sträussler-Scheinker disease, inclusion body myositis, prion protein cerebral amyloid angiopathy, traumatic brain injury, Guam amyotrophic lateral sclerosis / Parkinsonism dementia syndrome, non-Guam motor neuron disease with neurofibrillary tangles, argyrophilic grain dementia, glaucoma ... The tauopathy is selected from corticobasal degeneration, diffuse neurofibrillary tangle disease with calcifications, frontotemporal dementia, frontotemporal dementia with parkinsonism linked to chromosome 17, Hallervorden-Spatz disease, multiple system atrophy, Niemann-Pick disease type C, pallido-ponto-nigral degeneration, Pick's disease, progressive subcortical gliosis, progressive supranuclear palsy, subacute sclerosing panencephalitis, neurofibrillary tangle dementia, postencephalitic parkinsonism, and myotonic dystrophy. In some embodiments, the tauopathy is Alzheimer's disease or progressive supranuclear palsy. In some embodiments, the Tau protein-associated disease is selected from PART (primary age-related tauopathy), alteration-predominant dementia, subacute sclerosing panencephalopathy, chronic traumatic encephalopathy (CTE), white matter tauopathy with globular glial inclusions, Lewy body disease (LBD), mild cognitive impairment (MCI), glaucoma, familial British dementia, familial Danish dementia, Guadeloupian Parkinsonism, neurodegeneration with cerebral iron deposition, SLC9A6-associated intellectual disability, multiple sclerosis, HIV-associated dementia, senile cardiac amyloidosis, and Huntington's disease.

[0027] In some embodiments, the isolated antibodies described herein are provided for use in preserving or increasing cognitive memory capacity or slowing memory loss in an individual. In some embodiments, the isolated antibodies described herein are provided for use in reducing the level of Tau protein, phosphorylated Tau protein, non-phosphorylated Tau protein, or hyperphosphorylated Tau protein in an individual.

[0028] In some embodiments, the use of an antibody described herein is provided for the manufacture of a medicament for the treatment of a Tau protein-associated disease in an individual. In some embodiments, the Tau protein-associated disease is a tauopathy. In some embodiments, the tauopathy is a neurodegenerative tauopathy. In some embodiments, the tauopathy is Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, Creutzfeldt-Jakob disease, pugilistically impaired person, Down's syndrome, Gerstmann-Sträussler-Scheinker disease, inclusion body myositis, prion protein cerebral amyloid angiopathy, traumatic brain injury, Guam amyotrophic lateral sclerosis / Parkinsonism dementia syndrome, non-Guam motor neuron disease with neurofibrillary tangles, argyrophilic grain dementia, and glaucoma. The tauopathy is selected from corticobasal degeneration, diffuse neurofibrillary tangle disease with calcifications, frontotemporal dementia, frontotemporal dementia with parkinsonism linked to chromosome 17, Hallervorden-Spatz disease, multiple system atrophy, Niemann-Pick disease type C, pallido-ponto-nigral degeneration, Pick's disease, progressive subcortical gliosis, progressive supranuclear palsy, subacute sclerosing panencephalitis, neurofibrillary tangle dementia, postencephalitic parkinsonism, and myotonic dystrophy. In some embodiments, the tauopathy is Alzheimer's disease or progressive supranuclear palsy. In some embodiments, the Tau protein-associated disease is selected from PART (primary age-related tauopathy), alteration-predominant dementia, subacute sclerosing panencephalopathy, chronic traumatic encephalopathy (CTE), white matter tauopathy with globular glial inclusions, Lewy body disease (LBD), mild cognitive impairment (MCI), glaucoma, familial British dementia, familial Danish dementia, Guadeloupian Parkinsonism, neurodegeneration with cerebral iron deposition, SLC9A6-associated intellectual disability, multiple sclerosis, HIV-associated dementia, senile cardiac amyloidosis, and Huntington's disease.

[0029] In some embodiments, uses of the antibodies described herein are provided for the manufacture of a medicament for preserving or increasing cognitive memory capacity or slowing memory loss in an individual.

[0030] In some embodiments, a method for detecting neurofibrillary tangles, neuropil threads, or degenerated neurites is provided, comprising contacting a sample with an antibody described herein. In some embodiments, the sample is a brain sample, a cerebrospinal fluid sample, or a blood sample.

[0031] In any of the embodiments described herein, the method or use may include administering the antibody described herein in combination with at least one additional therapy. Non-limiting examples of additional therapies include neurological agents, corticosteroids, antibiotics, antiviral agents, and other therapeutic agents. Such other therapeutic agents include, but are not limited to, other anti-tau antibodies, antibodies against amyloid-beta, antibodies against beta-secretase 1 ("BACE1"), and inhibitors of beta-secretase 1. Further embodiments of the present invention [Embodiment 1] An isolated antibody that binds to human Tau, said antibody comprising HVR-H1 comprising the amino acid sequence of SEQ ID NO: 605, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 606, and HVR-H3 comprising the amino acid sequence of SEQ ID NO: 607. [Embodiment 2] 2. The antibody of embodiment 1, wherein the antibody comprises HVR-L1 comprising the amino acid sequence of SEQ ID NO: 608, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 609, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 610. [Embodiment 3] An isolated antibody that binds to human Tau, said antibody comprising HVR-L1 comprising the amino acid sequence of SEQ ID NO: 608, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 609, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 610. [Embodiment 4] An isolated antibody that binds to human Tau, said antibody comprising HVR-H1 comprising the amino acid sequence of SEQ ID NO: 605, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 606, HVR-H3 comprising the amino acid sequence of SEQ ID NO: 607, HVR-L1 comprising the amino acid sequence of SEQ ID NO: 608, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 609, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 610. [Embodiment 5] 2. The antibody of embodiment 1, wherein the antibody binds to monomeric Tau, oligomeric Tau, non-phosphorylated Tau, and phosphorylated Tau. [Embodiment 6] 3. The antibody of embodiment 1 or embodiment 2, wherein said antibody binds to an epitope within amino acids 2 to 24 of mature human Tau. [Embodiment 7] 4. The isolated antibody of any one of embodiments 1 to 3, which is a monoclonal antibody. [Embodiment 8] 2. The isolated antibody of any one of the preceding embodiments, which is a human, humanized, or chimeric antibody. [Embodiment 9] 2. The antibody of any one of the preceding embodiments, which is an antibody fragment that binds to human Tau. [Embodiment 10] 2. The antibody of any one of the preceding embodiments, wherein the human Tau comprises the sequence of SEQ ID NO:2. [Embodiment 11] The antibody a) a heavy chain variable region (VH) comprising a sequence at least 95% identical to SEQ ID NO: 603; b) a light chain variable region (VL) comprising a sequence at least 95% identical to SEQ ID NO: 604; c) VH as in (a) and VL as in (b); d) a heavy chain variable region (VH) comprising a sequence at least 95% identical to SEQ ID NO: 614; e) a light chain variable region (VL) comprising a sequence at least 95% identical to SEQ ID NO: 615; f) VH as in (d) and VL as in (e); g) a heavy chain variable region (VH) comprising a sequence at least 95% identical to SEQ ID NO: 619; h) a light chain variable region (VL) comprising a sequence at least 95% identical to SEQ ID NO: 620; i) An antibody according to any one of the preceding embodiments, comprising a VH as in (g) and a VL as in (h). [Embodiment 12] The antibody a) a heavy chain variable region (VH) comprising SEQ ID NO: 603; b) a light chain variable region (VL) comprising SEQ ID NO: 604; c) VH as in (a) and VL as in (b); d) a heavy chain variable region (VH) comprising the sequence of SEQ ID NO: 614; e) a light chain variable region (VL) comprising the sequence of SEQ ID NO: 615; f) VH as in (d) and VL as in (e); g) a heavy chain variable region (VH) comprising the sequence of SEQ ID NO: 619; h) a light chain variable region (VL) comprising the sequence of SEQ ID NO: 620; i) An antibody according to any one of the preceding embodiments, comprising a VH as in (g) and a VL as in (h). [Embodiment 13] 604, 615, and 620. [Embodiment 14] 340, 603, 614, and 619, and a light chain variable region comprising a sequence selected from SEQ ID NOs: 604, 615, and 620. [Embodiment 15] 10. The isolated antibody of any one of the preceding embodiments, wherein the antibody comprises a heavy chain variable region comprising a sequence selected from SEQ ID NOs: 603, 614, and 619, and a light chain variable region comprising a sequence selected from SEQ ID NOs: 341, 604, 615, and 620. [Embodiment 16] the antibody comprises: (a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 340 and a light chain variable region comprising a sequence selected from SEQ ID NOs: 604, 615, and 620; (b) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 603 and a light chain variable region comprising a sequence selected from SEQ ID NOs: 341, 604, 615, and 620; (c) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 614 and a light chain variable region comprising a sequence selected from SEQ ID NOs: 341, 604, 615, and 620; (d) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 619 and a light chain variable region comprising a sequence selected from SEQ ID NOs: 341, 604, 615, and 620; 603, 614, and 619, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 341; (f) a heavy chain variable region comprising a sequence selected from SEQ ID NOs: 340, 603, 614, and 619, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 604; (g) a heavy chain variable region comprising a sequence selected from SEQ ID NOs: 340, 603, 614, and 619, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 615; and (h) a heavy chain variable region comprising a sequence selected from SEQ ID NOs: 340, 603, 614, and 619, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 620. [Embodiment 17] 6. The isolated antibody of any one of the preceding embodiments, wherein the antibody comprises: (a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 603, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 604; (b) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 614, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 615; or (c) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 619, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 620. [Embodiment 18] 1. An isolated antibody that binds to human Tau, said antibody comprising: (a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 603, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 604; (b) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 614, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 615; or (c) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 619, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 620. [Embodiment 19] The antibody a) a heavy chain comprising an amino acid sequence at least 95%, at least 97%, or at least 99% identical to the sequence of SEQ ID NO: 611 or SEQ ID NO: 612, and a light chain comprising an amino acid sequence at least 95%, at least 97%, or at least 99% identical to the sequence of SEQ ID NO: 613; or b) a heavy chain comprising the amino acid sequence of SEQ ID NO: 611 or SEQ ID NO: 612, and a light chain comprising the amino acid sequence of SEQ ID NO: 613, or c) a heavy chain comprising an amino acid sequence at least 95%, at least 97%, or at least 99% identical to the sequence of SEQ ID NO: 616 or SEQ ID NO: 617, and a light chain comprising an amino acid sequence at least 95%, at least 97%, or at least 99% identical to the sequence of SEQ ID NO: 618; or d) a heavy chain comprising the amino acid sequence of SEQ ID NO: 616 or SEQ ID NO: 617, and a light chain comprising the amino acid sequence of SEQ ID NO: 618, or e) a heavy chain comprising an amino acid sequence at least 95%, at least 97%, or at least 99% identical to the sequence of SEQ ID NO: 621 or SEQ ID NO: 622, and a light chain comprising an amino acid sequence at least 95%, at least 97%, or at least 99% identical to the sequence of SEQ ID NO: 623; or f) An isolated antibody according to any one of the preceding embodiments, comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 621 or SEQ ID NO: 622, and a light chain comprising the amino acid sequence of SEQ ID NO: 623. [Embodiment 20] 1. An isolated antibody that binds to human Tau, the antibody comprising: (a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 611 or SEQ ID NO: 612, and a light chain comprising the amino acid sequence of SEQ ID NO: 613; (b) a heavy chain comprising the amino acid sequence of SEQ ID NO: 616 or SEQ ID NO: 617, and a light chain comprising the amino acid sequence of SEQ ID NO: 618; or (c) a heavy chain comprising the amino acid sequence of SEQ ID NO: 621 or SEQ ID NO: 622, and a light chain comprising the amino acid sequence of SEQ ID NO: 623. [Embodiment 21] 1. An isolated antibody that binds to human Tau, said antibody comprising: (a) a heavy chain consisting of the amino acid sequence of SEQ ID NO: 611 or SEQ ID NO: 612, and a light chain consisting of the amino acid sequence of SEQ ID NO: 613; (b) a heavy chain consisting of the amino acid sequence of SEQ ID NO: 616 or SEQ ID NO: 617, and a light chain consisting of the amino acid sequence of SEQ ID NO: 618; or (c) a heavy chain consisting of the amino acid sequence of SEQ ID NO: 621 or SEQ ID NO: 622, and a light chain consisting of the amino acid sequence of SEQ ID NO: 623. [Embodiment 22] 2. The isolated antibody of any one of the preceding embodiments, wherein the antibody is an IgG1 or IgG4 antibody. [Embodiment 23] 23. The isolated antibody of embodiment 22, wherein the antibody is an IgG4 antibody. [Embodiment 24] 24. The isolated antibody of embodiment 23, wherein the antibody comprises M252Y, S254T, and T256E mutations. [Embodiment 25] 25. The isolated antibody of embodiment 23 or embodiment 24, wherein the antibody comprises an S228P mutation. [Embodiment 26] 26. The isolated antibody of any one of embodiments 1 to 18 and 22 to 25, which is an antibody fragment. [Embodiment 27] The antibody has a K of less than 100 nM, less than 75 nM, less than 50 nM, less than 10 nM, less than 5 nM, or less than 1 nM for each of monomeric Tau, phosphorylated Tau, non-phosphorylated Tau, and oligomeric Tau. D 2. The isolated antibody of any one of the preceding embodiments, wherein the antibody binds at [Embodiment 28] The antibody has a K D 2. The isolated antibody of any one of the preceding embodiments, wherein the antibody binds at [Embodiment 29] K D 29. The isolated antibody of embodiment 27 or embodiment 28, wherein the antibody has a .alpha.-associated ... [Embodiment 30] 2. The isolated antibody of any one of the preceding embodiments, which binds to Cynomolgus Tau. [Embodiment 31] An isolated nucleic acid encoding the antibody of any one of the preceding embodiments. [Embodiment 32] A host cell comprising the nucleic acid described in embodiment 31. [Embodiment 33] 33. A method for producing an antibody, comprising culturing the host cell of embodiment 32 under conditions suitable for the production of said antibody. [Embodiment 34] An immunoconjugate comprising the isolated antibody of any one of embodiments 1 to 30 and a second therapeutic agent. [Embodiment 35] A labeled antibody comprising the antibody according to any one of embodiments 1 to 30 and a detectable label. [Embodiment 36] A pharmaceutical composition comprising an isolated antibody according to any one of embodiments 1 to 30 and a pharmaceutically acceptable carrier. [Embodiment 37] A method for treating a Tau protein-associated disease, the method comprising administering to an individual having a Tau protein-associated disease an antibody according to any one of embodiments 1 to 30 or a pharmaceutical composition according to embodiment 36. [Embodiment 38] 38. The method of embodiment 37, wherein the Tau protein-related disease is a tauopathy. [Embodiment 39] 39. The method of embodiment 38, wherein the tauopathy is a neurodegenerative tauopathy. [Embodiment 40] The tauopathy may be Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, Creutzfeldt-Jakob disease, pugilistically impaired person, Down's syndrome, Gerstmann-Sträussler-Scheinker disease, inclusion body myositis, prion protein cerebral amyloid angiopathy, traumatic brain injury, Guam amyotrophic lateral sclerosis / Parkinsonism dementia syndrome, non-Guam motor neuron disease with neurofibrillary tangles, argyrophilic grain dementia, corticobasal degeneration, diffuse neurofibrillary tangle disease with calcifications, frontotetemporal dementia, frontotetemporal dementia linked to Parkinsonism on chromosome 17, Hallervorden-Spatz disease, multiple system atrophy, Niemann-Pick disease type C, or pallidoponto-nigral degeneration. 39. The method of embodiment 37 or embodiment 38, wherein the disease is selected from: progressive subcortical gliosis, progressive supranuclear palsy, subacute sclerosing panencephalitis, neurofibrillary tangle dementia, postencephalitic parkinsonism, and myotonic dystrophy. [Embodiment 41] 41. The method according to any one of embodiments 38 to 40, wherein the tauopathy is Alzheimer's disease or progressive supranuclear palsy. [Embodiment 42] 37. A method for preserving or increasing cognitive memory capacity or slowing memory loss in an individual, the method comprising administering an antibody according to any one of embodiments 1 to 30, or a pharmaceutical composition according to embodiment 36. [Embodiment 43] 37. A method for reducing the level of Tau protein, non-phosphorylated Tau protein, phosphorylated Tau protein or hyperphosphorylated Tau protein in an individual, the method comprising administering an antibody according to any one of embodiments 1 to 30, or a pharmaceutical composition according to embodiment 36. [Embodiment 44] 44. The method according to any one of embodiments 37 to 43, wherein the method comprises administering at least one additional therapy. [Embodiment 45] 45. The method of embodiment 44, wherein the additional therapy is selected from a neurological agent, a corticosteroid, an antibiotic, an antiviral agent, an anti-Tau antibody, a Tau inhibitor, an anti-amyloid beta antibody, a beta-amyloid aggregation inhibitor, an anti-BACE1 antibody, and a BACE1 inhibitor. [Embodiment 46] An isolated antibody according to any one of embodiments 1 to 30 for use as a pharmaceutical. [Embodiment 47] 31. An isolated antibody according to any one of embodiments 1 to 30 for use in treating a tauopathy in an individual. [Embodiment 48] 48. The isolated antibody of embodiment 47, wherein the tauopathy is a neurodegenerative tauopathy. [Embodiment 49] The tauopathy may be Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, Creutzfeldt-Jakob disease, pugilistically impaired person, Down's syndrome, Gerstmann-Sträussler-Scheinker disease, inclusion body myositis, prion protein cerebral amyloid angiopathy, traumatic brain injury, Guam amyotrophic lateral sclerosis / Parkinsonism dementia syndrome, non-Guam motor neuron disease with neurofibrillary tangles, argyrophilic grain dementia, corticobasal degeneration, diffuse cerebrospinal fluid (CSF) with calcifications, or a combination thereof. 49. The isolated antibody of embodiment 47 or embodiment 48, wherein the antibody is selected from cancerous neurofibrillary tangle disease, frontotemporal dementia, frontotemporal dementia with parkinsonism linked to chromosome 17, Hallervorden-Spatz disease, multiple system atrophy, Niemann-Pick disease type C, pallido-pontocephalic-nigral degeneration, Pick's disease, progressive subcortical gliosis, progressive supranuclear palsy, subacute sclerosing panencephalitis, neurofibrillary tangle dementia, postencephalitic parkinsonism, and myotonic dystrophy. [Embodiment 50] 50. The isolated antibody of any one of embodiments 47 to 49, wherein the tauopathy is Alzheimer's disease or progressive supranuclear palsy. [Embodiment 51] 31. An isolated antibody according to any one of embodiments 1 to 30 for use in preserving or increasing cognitive memory capacity or slowing memory loss in an individual. [Embodiment 52] 31. The isolated antibody according to any one of embodiments 1 to 30 for use in reducing the level of Tau protein, phosphorylated Tau protein, non-phosphorylated Tau protein or hyperphosphorylated Tau protein in an individual. [Embodiment 53] 53. The isolated antibody of any one of embodiments 47 to 52, wherein the antibody is for use in conjunction with at least one additional therapy. [Embodiment 54] 54. The isolated antibody of embodiment 53, wherein the additional therapy is selected from a neurological agent, a corticosteroid, an antibiotic, an antiviral agent, an anti-Tau antibody, an anti-amyloid beta antibody, an anti-BACE1 antibody, and a BACE1 inhibitor. [Embodiment 55] 31. Use of an antibody according to any one of embodiments 1 to 30 for the manufacture of a medicament for the treatment of a Tau protein-related disease in an individual. [Embodiment 56] 56. The use according to embodiment 55, wherein the Tau protein-related disease is a tauopathy. [Embodiment 57] 57. The use according to embodiment 56, wherein the tauopathy is a neurodegenerative tauopathy. [Embodiment 58] The tauopathy may be Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, Creutzfeldt-Jakob disease, pugilistically impaired person, Down's syndrome, Gerstmann-Sträussler-Scheinker disease, inclusion body myositis, prion protein cerebral amyloid angiopathy, traumatic brain injury, Guam amyotrophic lateral sclerosis / Parkinsonism dementia syndrome, non-Guam motor neuron disease with neurofibrillary tangles, argyrophilic grain dementia, corticobasal degeneration, or calcification-associated tauopathy. 58. The use according to embodiment 56 or embodiment 57, wherein the disease is selected from diffuse neurofibrillary tangle disease, frontotemporal dementia, frontotemporal dementia with parkinsonism linked to chromosome 17, Hallervorden-Spatz disease, multiple system atrophy, Niemann-Pick disease type C, pallido-ponto-nigral degeneration, Pick's disease, progressive subcortical gliosis, progressive supranuclear palsy, subacute sclerosing panencephalitis, neurofibrillary tangle dementia, postencephalitic parkinsonism, and myotonic dystrophy. [Embodiment 59] The use according to any one of embodiments 56 to 58, wherein the tauopathy is Alzheimer's disease or progressive supranuclear palsy. [Embodiment 60] Use of an antibody according to any one of embodiments 1 to 30 for the manufacture of a medicament for preserving or increasing cognitive memory capacity or slowing down memory loss in an individual. [Embodiment 61] The use according to any one of embodiments 55 to 60, wherein the medicament is for administration together with at least one additional therapy. [Embodiment 62] 62. The use of embodiment 61, wherein the additional therapy is selected from neurological agents, corticosteroids, antibiotics, antiviral agents, anti-Tau antibodies, anti-amyloid beta antibodies, anti-BACE1 antibodies, and BACE1 inhibitors. [Embodiment 63] A method for detecting neurofibrillary tangles, neuropil threads, or degenerated neurites, the method comprising contacting a sample with the antibody according to any one of embodiments 1 to 30. [Embodiment 64] 64. The method of embodiment 63, wherein the sample is a brain sample, a cerebrospinal fluid sample, or a blood sample. <Sequence Listing> SEQUENCE LISTING <110> AC IMMUNE SA GENENTECH, INC. <120> ANTI-TAU ANTIBODIES AND METHODS OF USE <130> 01147-0007-00PCT <150> US 62 / 431,180 <151> 2016-12-07 <160> 624 <170> PatentIn version 3.5 <210> 1 <211> 456 <212> PRT <213> Homo sapiens <220> <221> misc_feature <223> Human Tau sequence <400> 1 Met His His His His His His Gly Glu Asn Leu Tyr Phe Gln Gly Ser 1 5 10 15 Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly Thr 20 25 30 Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His Gln 35 40 45 Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu Gln 50 55 60 Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser Asp 65 70 75 80 Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val Asp 85 90 95 Glu Gly Ala Pro Gly Lys Gln Ala Ala Ala Gln Pro His Thr Glu Ile 100 105 110 Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro Ser 115 120 125 Leu Glu Asp Glu Ala Ala Gly His Val Thr Gln Ala Arg Met Val Ser 130 135 140 Lys Ser Lys Asp Gly Thr Gly Ser Asp Asp Lys Lys Ala Lys Gly Ala 145 150 155 160 Asp Gly Lys Thr Lys Ile Ala Thr Pro Arg Gly Ala Ala Pro Pro Gly 165 170 175 Gln Lys Gly Gln Ala Asn Ala Thr Arg Ile Pro Ala Lys Thr Pro Pro 180 185 190 Ala Pro Lys Thr Pro Pro Ser Ser Gly Glu Pro Pro Lys Ser Gly Asp 195 200 205 Arg Ser Gly Tyr Ser Ser Pro Gly Ser Pro Gly Thr Pro Gly Ser Arg 210 215 220 Ser Arg Thr Pro Ser Leu Pro Thr Pro Pro Thr Arg Glu Pro Lys Lys 225 230 235 240 Val Ala Val Val Arg Thr Pro Pro Lys Ser Pro Ser Ser Ala Lys Ser 245 250 255 Arg Leu Gln Thr Ala Pro Val Pro Met Pro Asp Leu Lys Asn Val Lys 260 265 270 Ser Lys Ile Gly Ser Thr Glu Asn Leu Lys His Gln Pro Gly Gly Gly 275 280 285 Lys Val Gln Ile Ile Asn Lys Lys Leu Asp Leu Ser Asn Val Gln Ser 290 295 300 Lys Cys Gly Ser Lys Asp Asn Ile Lys His Val Pro Gly Gly Gly Ser 305 310 315 320 Val Gln Ile Val Tyr Lys Pro Val Asp Leu Ser Lys Val Thr Ser Lys 325 330 335 Cys Gly Ser Leu Gly Asn Ile His His Lys Pro Gly Gly Gly Gln Val 340 345 350 Glu Val Lys Ser Glu Lys Leu Asp Phe Lys Asp Arg Val Gln Ser Lys 355 360 365 Ile Gly Ser Leu Asp Asn Ile Thr His Val Pro Gly Gly Gly Asn Lys 370 375 380 Lys Ile Glu Thr His Lys Leu Thr Phe Arg Glu Asn Ala Lys Ala Lys 385 390 395 400 Thr Asp His Gly Ala Glu Ile Val Tyr Lys Ser Pro Val Val Ser Gly 405 410 415 Asp Thr Ser Pro Arg His Leu Ser Asn Val Ser Ser Thr Gly Ser Ile 420 425 430 Asp Met Val Asp Ser Pro Gln Leu Ala Thr Leu Ala Asp Glu Val Ser 435 440 445 Ala Ser Leu Ala Lys Gln Gly Leu 450 455 <210> 2 <211> 23 <212> PRT <213> Homo sapiens <220> <221> misc_feature <223> Human Tau epitope (2-24) <400> 2 Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly Thr 1 5 10 15 Tyr Gly Leu Gly Asp Arg Lys 20 <210> 3 <211> 456 <212> PRT <213> Macaca fascicularis <220> <221> misc_feature <223> Cynomolgus monkey Tau sequence <400> 3 Met His His His His His His Gly Glu Asn Leu Tyr Phe Gln Gly Ser 1 5 10 15 Ala Glu Pro Arg Gln Glu Phe Asp Val Met Glu Asp His Ala Gly Thr 20 25 30 Tyr Gly Leu Gly Asp Arg Lys Asp Gln Glu Gly Tyr Thr Met Leu Gln 35 40 45 Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu Gln 50 55 60 Thr Pro Ala Glu Asp Gly Ser Glu Glu Leu Gly Ser Glu Thr Ser Asp 65 70 75 80 Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val Asp 85 90 95 Glu Arg Ala Pro Gly Glu Gln Ala Ala Ala Gln Pro His Met Glu Ile 100 105 110 Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro Ser 115 120 125 Leu Glu Asp Glu Ala Ala Gly His Val Thr Gln Ala Arg Met Val Ser 130 135 140 Lys Ser Lys Asp Gly Thr Gly Ser Asp Asp Lys Lys Ala Lys Gly Ala 145 150 155 160 Asp Gly Lys Thr Lys Ile Ala Thr Pro Arg Gly Ala Ala Pro Pro Gly 165 170 175 Gln Lys Gly Gln Ala Asn Ala Thr Arg Ile Pro Ala Lys Thr Pro Pro 180 185 190 Ala Pro Lys Thr Pro Pro Ser Ser Gly Glu Pro Pro Lys Ser Gly Asp 195 200 205 Arg Ser Gly Tyr Ser Ser Pro Gly Ser Pro Gly Thr Pro Gly Ser Arg 210 215 220 Ser Arg Thr Pro Ser Leu Pro Thr Pro Pro Ala Arg Glu Pro Lys Lys 225 230 235 240 Val Ala Val Val Arg Thr Pro Pro Lys Ser Pro Ser Ser Ala Lys Ser 245 250 255 Arg Leu Gln Thr Ala Pro Val Pro Met Pro Asp Leu Lys Asn Val Lys 260 265 270 Ser Lys Ile Gly Ser Thr Glu Asn Leu Lys His Gln Pro Gly Gly Gly 275 280 285 Lys Val Gln Ile Ile Asn Lys Lys Leu Asp Leu Ser Asn Val Gln Ser 290 295 300 Lys Cys Gly Ser Lys Asp Asn Ile Lys His Val Pro Gly Gly Gly Ser 305 310 315 320 Val Gln Ile Val Tyr Lys Pro Val Asp Leu Ser Lys Val Thr Ser Lys 325 330 335 Cys Gly Ser Leu Gly Asn Ile His His Lys Pro Gly Gly Gly Gln Val 340 345 350 Glu Val Lys Ser Glu Lys Leu Asp Phe Lys Asp Arg Val Gln Ser Lys 355 360 365 Ile Gly Ser Leu Asp Asn Ile Thr His Val Pro Gly Gly Gly Asn Lys 370 375 380 Lys Ile Glu Thr His Lys Leu Thr Phe Arg Glu Asn Ala Lys Ala Lys 385 390 395 400 Thr Asp His Gly Ala Glu Ile Val Tyr Lys Ser Pro Val Val Ser Gly 405 410 415 Asp Thr Ser Pro Arg His Leu Ser Asn Val Ser Ser Thr Gly Ser Ile 420 425 430 Asp Met Val Asp Ser Pro Gln Leu Ala Thr Leu Ala Asp Glu Val Ser 435 440 445 Ala Ser Leu Ala Lys Gln Gly Leu 450 455 <210> 4 <211> 23 <212> PRT <213> Macaca fascicularis <220> <221> misc_feature <223> Cynomolgus monkey Tau epitope (2-24) <400> 4 Ala Glu Pro Arg Gln Glu Phe Asp Val Met Glu Asp His Ala Gly Thr 1 5 10 15 Tyr Gly Leu Gly Asp Arg Lys 20 <210> 5 <400> 5 000 <210> 6 <400> 6 000 <210> 7 <400> 7 000 <210> 8 <400> 8 000 <210> 9 <400> 9 000 <210> 10 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 37D3-H9 heavy chain variable region (VH) <400> 10 Glu Val Gln Leu Val Glu Ser Gly Gly Asp Leu Ala Lys Pro Gly Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Thr Ala Ser Gly Leu Ile Phe Arg Ser Tyr 20 25 30 Gly Met Ser Trp Val Arg Gln Thr Pro Asp Lys Arg Leu Glu Trp Val 35 40 45 Ala Thr Ile Asn Ser Gly Gly Thr Tyr Thr Tyr Tyr Pro Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr Cys 85 90 95 Ala Asn Ser Tyr Ser Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser 100 105 110 Val Thr Val Ser Ser 115 <210> 11 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 37D3-H9 light chain variable region (VL) <400> 11 Asp Asp Leu Leu Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 1 5 10 15 Asp Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser 20 25 30 Asn Gly Asn Thr Tyr Phe Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Phe Gln Gly 85 90 95 Ser Leu Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 12 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 37D3-H9 HVR-H1 <400> 12 Ser Tyr Gly Met Ser 1 5 <210> 13 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 37D3-H9 HVR-H2 <400> 13 Thr Ile Asn Ser Gly Gly Thr Tyr Thr Tyr Tyr Pro Asp Ser Val Lys 1 5 10 15 Gly <210> 14 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 37D3-H9 HVR-H3 <400> 14 Ser Tyr Ser Gly Ala Met Asp Tyr 1 5 <210> 15 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 37D3-H9 HVR-L1 <400> 15 Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Asn Thr Tyr Phe Glu 1 5 10 15 <210> 16 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 37D3-H9 HVR-L2 <400> 16 Lys Val Ser Asn Arg Phe Ser 1 5 <210> 17 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 37D3-H9 HVR-L3 <400> 17 Phe Gln Gly Ser Leu Val Pro Trp Thr 1 5 <210> 18 <400> 18 000 <210> 19 <400> 19 000 <210> 20 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 37D3-H9b heavy chain variable region (VH) <400> 20 Glu Val Gln Leu Val Glu Ser Gly Gly Asp Leu Ala Lys Pro Gly Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Thr Ala Ser Gly Leu Ile Phe Arg Ser Tyr 20 25 30 Gly Met Ser Trp Val Arg Gln Thr Pro Asp Lys Arg Leu Glu Trp Val 35 40 45 Ala Thr Ile Asn Ser Gly Gly Thr Tyr Thr Tyr Tyr Pro Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr Cys 85 90 95 Ala Asn Ser Tyr Ser Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser 100 105 110 Val Thr Val Ser Ser 115 <210> 21 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 37D3-H9b light chain variable region (VL) <400> 21 Glu Asp Leu Leu Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 1 5 10 15 Asp Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser 20 25 30 Asn Gly Asn Thr Tyr Phe Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Phe Gln Gly 85 90 95 Ser Leu Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 22 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 37D3-H9b HVR-H1 <400> 22 Ser Tyr Gly Met Ser 1 5 <210> 23 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 37D3-H9b HVR-H2 <400> 23 Thr Ile Asn Ser Gly Gly Thr Tyr Thr Tyr Tyr Pro Asp Ser Val Lys 1 5 10 15 Gly <210> 24 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 37D3-H9b HVR-H3 <400> 24 Ser Tyr Ser Gly Ala Met Asp Tyr 1 5 <210> 25 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 37D3-H9b HVR-L1 <400> 25 Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Asn Thr Tyr Phe Glu 1 5 10 15 <210> 26 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 37D3-H9b HVR-L2 <400> 26 Lys Val Ser Asn Arg Phe Ser 1 5 <210> 27 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 37D3-H9b HVR-L3 <400> 27 Phe Gln Gly Ser Leu Val Pro Trp Thr 1 5 <210> 28 <400> 28 000 <210> 29 <400> 29 000 <210> 30 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 11E10-B8 heavy chain variable region (VH) <400> 30 Glu Val Gln Leu Val Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Ser Tyr 20 25 30 Gly Met Ser Trp Val Arg Gln Thr Pro Asp Lys Arg Leu Glu Trp Val 35 40 45 Ala Thr Ile Ser Gly Gly Gly Ser Tyr Thr Tyr Tyr Pro Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr Cys 85 90 95 Ala Val Ser Tyr Asp Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser 100 105 110 Val Thr Val Ser Ser 115 <210> 31 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 11E10-B8 light chain variable region (VL) <400> 31 Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 1 5 10 15 Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser 20 25 30 Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Leu Gly Leu Tyr Tyr Cys Phe Gln Gly 85 90 95 Ser His Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 32 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 11E10-B8 HVR-H1 <400> 32 Ser Tyr Gly Met Ser 1 5 <210> 33 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 11E10-B8 HVR-H2 <400> 33 Thr Ile Ser Gly Gly Gly Ser Tyr Thr Tyr Tyr Pro Asp Ser Val Lys 1 5 10 15 Gly <210> 34 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 11E10-B8 HVR-H3 <400> 34 Ser Tyr Asp Gly Ala Met Asp Tyr 1 5 <210> 35 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 11E10-B8 HVR-L1 <400> 35 Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Asn Thr Tyr Leu Glu 1 5 10 15 <210> 36 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 11E10-B8 HVR-L2 <400> 36 Lys Val Ser Asn Arg Phe Ser 1 5 <210> 37 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 11E10-B8 HVR-L3 <400> 37 Phe Gln Gly Ser His Val Pro Trp Thr 1 5 <210> 38 <400> 38 000 <210> 39 <400> 39 000 <210> 40 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 54C1-H11 and 61E7-C4 heavy chain variable region (VH) <400> 40 Glu Val Gln Leu Val Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Lys Val Ser Cys Val Ala Ser Gly Phe Thr Phe Arg Ser Tyr 20 25 30 Gly Met Ser Trp Val Arg Gln Thr Pro Asp Lys Arg Leu Asp Trp Val 35 40 45 Ala Thr Ile Ser Ser Gly Gly Asn Tyr Thr Tyr Tyr Pro Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr Cys 85 90 95 Ala Ser Ser Tyr Ser Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser 100 105 110 Val Thr Val Ser Ser 115 <210> 41 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 54C1-H11 and 61E7-C4 light chain variable region (VL) <400> 41 Asp Thr Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Ser Leu Gly 1 5 10 15 Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser 20 25 30 Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Lys Leu Leu Ile Tyr Thr Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Phe Gln Gly 85 90 95 Ser His Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 42 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 54C1-H11 and 61E7-C4 HVR-H1 <400> 42 Ser Tyr Gly Met Ser 1 5 <210> 43 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 54C1-H11 and 61E7-C4 HVR-H2 <400> 43 Thr Ile Ser Ser Gly Gly Asn Tyr Thr Tyr Tyr Pro Asp Ser Val Lys 1 5 10 15 Gly <210> 44 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 54C1-H11 and 61E7-C4 HVR-H3 <400> 44 Ser Tyr Ser Gly Ala Met Asp Tyr 1 5 <210> 45 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 54C1-H11 and 61E7-C4 HVR-L1 <400> 45 Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Asn Thr Tyr Leu Glu 1 5 10 15 <210> 46 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 54C1-H11 and 61E7-C4 HVR-L2 <400> 46 Thr Val Ser Asn Arg Phe Ser 1 5 <210> 47 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 54C1-H11 and 61E7-C4 HVR-L3 <400> 47 Phe Gln Gly Ser His Val Pro Trp Thr 1 5 <210> 48 <400> 48 000 <210> 49 <400> 49 000 <210> 50 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 3A4-H4 heavy chain variable region (VH) <400> 50 Glu Val Gln Leu Val Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Gly Met Ser Trp Val Arg Gln Thr Pro Asp Lys Arg Leu Glu Trp Val 35 40 45 Ala Thr Ile Ser Ser Gly Gly Thr Tyr Thr Tyr Tyr Pro Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Phe Cys 85 90 95 Ala Thr Ser Tyr Asp Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser 100 105 110 Val Thr Val Ser Ser 115 <210> 51 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 3A4-H4 light chain variable region (VL) <400> 51 Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 1 5 10 15 Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Asn Ile Val His Ser 20 25 30 Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Phe Gln Gly 85 90 95 Thr Leu Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 52 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 3A4-H4 HVR-H1 <400> 52 Ser Tyr Gly Met Ser 1 5 <210> 53 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 3A4-H4 HVR-H2 <400> 53 Thr Ile Ser Ser Gly Gly Thr Tyr Thr Tyr Tyr Pro Asp Ser Val Lys 1 5 10 15 Gly <210> 54 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 3A4-H4 HVR-H3 <400> 54 Ser Tyr Asp Gly Ala Met Asp Tyr 1 5 <210> 55 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 3A4-H4 HVR-L1 <400> 55 Arg Ser Ser Gln Asn Ile Val His Ser Asn Gly Asn Thr Tyr Leu Glu 1 5 10 15 <210> 56 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 3A4-H4 HVR-L2 <400> 56 Lys Val Ser Asn Arg Phe Ser 1 5 <210> 57 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 3A4-H4 HVR-L3 <400> 57 Phe Gln Gly Thr Leu Val Pro Trp Thr 1 5 <210> 58 <400> 58 000 <210> 59 <400> 59 000 <210> 60 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 19H6-F7 heavy chain variable region (VH) <400> 60 Glu Val Gln Leu Val Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Gly Met Ser Trp Val Arg Gln Thr Pro Asp Lys Arg Leu Glu Trp Val 35 40 45 Ala Thr Ile Ser Ser Gly Gly Thr Tyr Thr Tyr Tyr Pro Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr Cys 85 90 95 Ala Pro Ser Tyr Asp Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser 100 105 110 Val Thr Val Ser Ser 115 <210> 61 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 19H6-F7 light chain variable region (VL) <400> 61 Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 1 5 10 15 Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser 20 25 30 Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Phe Gln Gly 85 90 95 Ser Leu Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 62 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 19H6-F7 HVR-H1 <400> 62 Ser Tyr Gly Met Ser 1 5 <210> 63 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 19H6-F7 HVR-H2 <400> 63 Thr Ile Ser Ser Gly Gly Thr Tyr Thr Tyr Tyr Pro Asp Ser Val Lys 1 5 10 15 Gly <210> 64 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 19H6-F7 HVR-H3 <400> 64 Ser Tyr Asp Gly Ala Met Asp Tyr 1 5 <210> 65 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 19H6-F7 HVR-L1 <400> 65 Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Asn Thr Tyr Leu Glu 1 5 10 15 <210> 66 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 19H6-F7 HVR-L2 <400> 66 Lys Val Ser Asn Arg Phe Ser 1 5 <210> 67 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 19H6-F7 HVR-L3 <400> 67 Phe Gln Gly Ser Leu Val Pro Trp Thr 1 5 <210> 68 <400> 68 000 <210> 69 <400> 69 000 <210> 70 <211> 113 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 94B2-C1 heavy chain variable region (VH) <400> 70 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Met Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Leu Thr Gly Tyr 20 25 30 Thr Met Asn Trp Val Lys Gln Ser His Gly Lys Asn Leu Glu Trp Ile 35 40 45 Gly Leu Ile Ser Pro Tyr Asn Gly Val Thr Ser Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Asn Thr Ala Tyr 65 70 75 80 Met Glu Leu Leu Ser Leu Thr Phe Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gln Gly Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser 100 105 110 Ala <210> 71 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 94B2-C1 light chain variable region (VL) <400> 71 Asp Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser Val Thr Ile Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser 20 25 30 Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser 35 40 45 Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro 50 55 60 Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Trp Gln Gly 85 90 95 Thr His Phe Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 72 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 94B2-C1 HVR-H1 <400> 72 Gly Tyr Thr Met Asn 1 5 <210> 73 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 94B2-C1 HVR-H2 <400> 73 Leu Ile Ser Pro Tyr Asn Gly Val Thr Ser Tyr Asn Gln Lys Phe Lys 1 5 10 15 Gly <210> 74 <211> 4 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 94B2-C1 HVR-H3 <400> 74 Gln Gly Ala Tyr 1 <210> 75 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 94B2-C1 HVR-L1 <400> 75 Lys Ser Ser Gln Ser Leu Leu Asp Ser Asp Gly Lys Thr Tyr Leu Asn 1 5 10 15 <210> 76 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 94B2-C1 HVR-L2 <400> 76 Leu Val Ser Lys Leu Asp Ser 1 5 <210> 77 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 94B2-C1 HVR-L3 <400> 77 Trp Gln Gly Thr His Phe Pro Trp Thr 1 5 <210> 78 <400> 78 000 <210> 79 <400> 79 000 <210> 80 <211> 115 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 125B11-H3 heavy chain variable region (VH) <400> 80 Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Met Lys Leu Ser Cys Val Ala Ser Arg Phe Ile Phe Ser Asn Tyr 20 25 30 Trp Met Asn Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Ala Gln Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 65 70 75 80 Val Tyr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Gly Ile Tyr 85 90 95 Tyr Cys Thr Gly Gly Thr Thr Tyr Trp Gly Gln Gly Thr Thr Leu Thr 100 105 110 Val Ser Ser 115 <210> 81 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 125B11-H3 light chain variable region (VL) <400> 81 Asp Ile Val Met Thr Gln Ser Gln Lys Phe Leu Ser Thr Ser Val Gly 1 5 10 15 Asp Arg Val Asn Ile Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Gly Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Ile Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly 50 55 60 Asn Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asp Met Gln Ser 65 70 75 80 Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Phe Arg Thr Tyr Pro Tyr 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 82 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 125B11-H3 HVR-H1 <400> 82 Asn Tyr Trp Met Asn 1 5 <210> 83 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 125B11-H3 HVR-H2 <400> 83 Gln Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu Ser 1 5 10 15 Val Lys Gly <210> 84 <211> 4 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 125B11-H3 HVR-H3 <400> 84 Gly Thr Thr Tyr 1 <210> 85 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 125B11-H3 HVR-L1 <400> 85 Lys Ala Ser Gln Asn Val Gly Thr Ala Val Ala 1 5 10 <210> 86 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 125B11-H3 HVR-L2 <400> 86 Ser Ala Ser Ile Arg Tyr Thr 1 5 <210> 87 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 125B11-H3 HVR-L3 <400> 87 Gln Gln Phe Arg Thr Tyr Pro Tyr Thr 1 5 <210> 88 <400> 88 000 <210> 89 <400> 89 000 <210> 90 <211> 115 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 113F5-F7 heavy chain variable region (VH) <400> 90 Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Met Arg Leu Ser Cys Val Ala Ser Glu Phe Thr Phe Ser Asn Tyr 20 25 30 Trp Met Asn Trp Ile Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Ala Gln Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Ala Ser Asn Phe Ser 65 70 75 80 Val Tyr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Gly Ile Tyr 85 90 95 Tyr Cys Thr Gly Gly Thr Ser Tyr Trp Gly Gln Gly Thr Thr Leu Thr 100 105 110 Val Ser Ser 115 <210> 91 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 113F5-F7 light chain variable region (VL) <400> 91 Asp Ile Val Met Thr Gln Ser Gln Lys Ile Met Ser Thr Ser Val Gly 1 5 10 15 Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Ala 20 25 30 Val Ala Trp Tyr Gln Gln Arg Pro Gly His Ser Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Arg Arg Phe Ser Gly Val Pro Asp Arg Phe Thr Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ile Asn Val Gln Ser 65 70 75 80 Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Phe Ser Thr Tyr Pro Tyr 85 90 95 Thr Phe Gly Val Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 92 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 113F5-F7 HVR-H1 <400> 92 Asn Tyr Trp Met Asn 1 5 <210> 93 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 113F5-F7 HVR-H2 <400> 93 Gln Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu Ser 1 5 10 15 Val Lys Gly <210> 94 <211> 4 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 113F5-F7 HVR-H3 <400> 94 Gly Thr Ser Tyr 1 <210> 95 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 113F5-F7 HVR-L1 <400> 95 Lys Ala Ser Gln Asn Val Gly Thr Ala Val Ala 1 5 10 <210> 96 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 113F5-F7 HVR-L2 <400> 96 Ser Ala Ser Arg Arg Phe Ser 1 5 <210> 97 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 113F5-F7 HVR-L3 <400> 97 Gln Gln Phe Ser Thr Tyr Pro Tyr Thr 1 5 <210> 98 <400> 98 000 <210> 99 <400> 99 000 <210> 100 <211> 121 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 26C1-B11 heavy chain variable region (VH) <400> 100 Glu Val His Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Ser Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Tyr 20 25 30 Tyr Met Tyr Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 35 40 45 Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr Glu Tyr Phe Pro Lys Phe 50 55 60 Gln Gly Lys Ala Thr Met Thr Ala Asp Thr Ser Ser Lys Thr Ala Tyr 65 70 75 80 Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Asn Ala Trp Arg Ala Arg Ala Thr Asn Ser Ala Leu Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Ser Val Thr Val Ser Ser 115 120 <210> 101 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 26C1-B11 light chain variable region (VL) <400> 101 Asp Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser Val Thr Ile Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser 20 25 30 Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Arg Arg Pro Gly Gln Ser 35 40 45 Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro 50 55 60 Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Trp Gln Gly 85 90 95 Thr His Phe Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 102 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 26C1-B11 HVR-H1 <400> 102 Asp Tyr Tyr Met Tyr 1 5 <210> 103 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 26C1-B11 HVR-H2 <400> 103 Trp Ile Asp Pro Glu Asn Gly Asp Thr Glu Tyr Phe Pro Lys Phe Gln 1 5 10 15 Gly <210> 104 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 26C1-B11 HVR-H3 <400> 104 Trp Arg Ala Arg Ala Thr Asn Ser Ala Leu Asp Tyr 1 5 10 <210> 105 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 26C1-B11 HVR-L1 <400> 105 Lys Ser Ser Gln Ser Leu Leu Asp Ser Asp Gly Lys Thr Tyr Leu Asn 1 5 10 15 <210> 106 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 26C1-B11 HVR-L2 <400> 106 Leu Val Ser Lys Leu Asp Ser 1 5 <210> 107 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 26C1-B11 HVR-L3 <400> 107 Trp Gln Gly Thr His Phe Pro Trp Thr 1 5 <210> 108 <400> 108 000 <210> 109 <400> 109 000 <210> 110 <211> 121 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 26C1-C8 heavy chain variable region (VH) <400> 110 Glu Val His Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Ser Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Tyr 20 25 30 Tyr Met Tyr Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 35 40 45 Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr Glu Tyr Phe Pro Lys Phe 50 55 60 Gln Gly Lys Ala Thr Met Thr Ala Asp Thr Ser Ser Lys Thr Ala Tyr 65 70 75 80 Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Asn Ala Trp Arg Ala Arg Ala Thr Asn Ser Ala Leu Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Ser Val Thr Val Ser Ser 115 120 <210> 111 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 26C1-C8 light chain variable region (VL) <400> 111 Asp Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser Val Thr Ile Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser 20 25 30 Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Arg Arg Pro Gly Gln Ser 35 40 45 Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro 50 55 60 Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Trp Gln Gly 85 90 95 Thr His Phe Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 112 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 26C1-C8 HVR-H1 <400> 112 Asp Tyr Tyr Met Tyr 1 5 <210> 113 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 26C1-C8 HVR-H2 <400> 113 Trp Ile Asp Pro Glu Asn Gly Asp Thr Glu Tyr Phe Pro Lys Phe Gln 1 5 10 15 Gly <210> 114 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 26C1-C8 HVR-H3 <400> 114 Trp Arg Ala Arg Ala Thr Asn Ser Ala Leu Asp Tyr 1 5 10 <210> 115 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 26C1-C8 HVR-L1 <400> 115 Lys Ser Ser Gln Ser Leu Leu Asp Ser Asp Gly Lys Thr Tyr Leu Asn 1 5 10 15 <210> 116 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 26C1-C8 HVR-L2 <400> 116 Leu Val Ser Lys Leu Asp Ser 1 5 <210> 117 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 26C1-C8 HVR-L3 <400> 117 Trp Gln Gly Thr His Phe Pro Trp Thr 1 5 <210> 118 <400> 118 000 <210> 119 <400> 119 000 <210> 120 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 30G1-B2 heavy chain variable region (VH) <400> 120 Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala 1 5 10 15 Ser Val Thr Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Glu Met Tyr Trp Val Lys Gln Thr Pro Val His Gly Leu Glu Trp Ile 35 40 45 Gly Ala Ile Asp Pro Glu Thr Gly Asp Thr Ala Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Asn Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ile Arg Gln Tyr Gly Asn Trp Phe Pro Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ala 115 <210> 121 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 30G1-B2 light chain variable region (VL) <400> 121 Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 1 5 10 15 Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ala 20 25 30 Asn Gly Asn Thr Tyr Leu His Trp Phe Leu Gln Lys Pro Gly Leu Ser 35 40 45 Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Gly Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Thr Arg Leu Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser 85 90 95 Thr His Val Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 122 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 30G1-B2 HVR-H1 <400> 122 Asp Tyr Glu Met Tyr 1 5 <210> 123 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 30G1-B2 HVR-H2 <400> 123 Ala Ile Asp Pro Glu Thr Gly Asp Thr Ala Tyr Asn Gln Lys Phe Lys 1 5 10 15 Gly <210> 124 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 30G1-B2 HVR-H3 <400> 124 Gln Tyr Gly Asn Trp Phe Pro Tyr 1 5 <210> 125 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 30G1-B2 HVR-L1 <400> 125 Arg Ser Ser Gln Ser Leu Val His Ala Asn Gly Asn Thr Tyr Leu His 1 5 10 15 <210> 126 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 30G1-B2 HVR-L2 <400> 126 Lys Val Ser Asn Arg Phe Ser 1 5 <210> 127 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 30G1-B2 HVR-L3 <400> 127 Ser Gln Ser Thr His Val Pro Phe Thr 1 5 <210> 128 <400> 128 000 <210> 129 <400> 129 000 <210> 130 <211> 114 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 66F5-A1 heavy chain variable region (VH) <400> 130 Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala 1 5 10 15 Ser Val Thr Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ile Asp Tyr 20 25 30 Glu Met Asn Trp Val Lys Gln Thr Pro Val His Gly Leu Glu Trp Ile 35 40 45 Gly Ala Ile Asp Pro Glu Asn Gly Gly Thr Ala Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Ala Ile Val Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ser Gly Pro His Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 100 105 110 Ser Ser <210> 131 <211> 113 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 66F5-A1 light chain variable region (VL) <400> 131 Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ala Met Ser Val Gly 1 5 10 15 Gln Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser 20 25 30 Ser Thr Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 35 40 45 Ser Pro Lys Leu Leu Val Tyr Phe Ala Ser Thr Arg Glu Ser Gly Val 50 55 60 Pro Asp Arg Phe Ile Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 65 70 75 80 Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln 85 90 95 His Tyr Ser Thr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile 100 105 110 Lys <210> 132 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 66F5-A1 HVR-H1 <400> 132 Asp Tyr Glu Met Asn 1 5 <210> 133 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 66F5-A1 HVR-H2 <400> 133 Ala Ile Asp Pro Glu Asn Gly Gly Thr Ala Tyr Asn Gln Lys Phe Lys 1 5 10 15 Gly <210> 134 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 66F5-A1 HVR-H3 <400> 134 Pro His Phe Asp Tyr 1 5 <210> 135 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 66F5-A1 HVR-L1 <400> 135 Lys Ser Ser Gln Ser Leu Leu Asn Ser Ser Thr Gln Lys Asn Tyr Leu 1 5 10 15 Ala <210> 136 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 66F5-A1 HVR-L2 <400> 136 Phe Ala Ser Thr Arg Glu Ser 1 5 <210> 137 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 66F5-A1 HVR-L3 <400> 137 Gln Gln His Tyr Ser Thr Pro Tyr Thr 1 5 <210> 138 <400> 138 000 <210> 139 <400> 139 000 <210> 140 <211> 119 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 123E9-A1 heavy chain variable region (VH) <400> 140 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Tyr Met Lys Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 35 40 45 Gly Asp Ile Asp Pro Asn Asn Gly Gly Thr Ser Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ser Ala Gly Phe Gly Asp Ser Phe Ser Phe Trp Gly Leu Gly 100 105 110 Thr Leu Val Thr Val Ser Ala 115 <210> 141 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 123E9-A1 light chain variable region (VL) <400> 141 Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 1 5 10 15 Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser 20 25 30 Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Leu Gly Phe Tyr Tyr Cys Phe Gln Gly 85 90 95 Ser His Val Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 142 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 123E9-A1 HVR-H1 <400> 142 Asp Tyr Tyr Met Lys 1 5 <210> 143 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 123E9-A1 HVR-H2 <400> 143 Asp Ile Asp Pro Asn Asn Gly Gly Thr Ser Tyr Asn Gln Lys Phe Lys 1 5 10 15 Gly <210> 144 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 123E9-A1 HVR-H3 <400> 144 Ser Ala Gly Phe Gly Asp Ser Phe Ser Phe 1 5 10 <210> 145 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 123E9-A1 HVR-L1 <400> 145 Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Asn Thr Tyr Leu Glu 1 5 10 15 <210> 146 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 123E9-A1 HVR-L2 <400> 146 Lys Val Ser Asn Arg Phe Ser 1 5 <210> 147 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 123E9-A1 HVR-L3 <400> 147 Phe Gln Gly Ser His Val Pro Pro Thr 1 5 <210> 148 <400> 148 000 <210> 149 <400> 149 000 <210> 150 <211> 119 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 15C6-A7 heavy chain variable region (VH) <400> 150 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Met Met Thr Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Tyr Met Lys Trp Val Lys Gln Ser Asn Gly Lys Ser Leu Glu Trp Ile 35 40 45 Gly Asp Leu Asp Pro Tyr Thr Gly Gly Ala Asn Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met His Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ser Arg Gly Tyr Gly Asp Ser Phe Ala Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ala 115 <210> 151 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 15C6-A7 light chain variable region (VL) <400> 151 Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 1 5 10 15 Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Asn Ile Val His Ser 20 25 30 Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Lys Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Phe Gln Gly 85 90 95 Ser His Val Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 152 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 15C6-A7 HVR-H1 <400> 152 Asp Tyr Tyr Met Lys 1 5 <210> 153 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 15C6-A7 HVR-H2 <400> 153 Asp Leu Asp Pro Tyr Thr Gly Gly Ala Asn Tyr Asn Gln Lys Phe Lys 1 5 10 15 Gly <210> 154 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 15C6-A7 HVR-H3 <400> 154 Ser Arg Gly Tyr Gly Asp Ser Phe Ala Tyr 1 5 10 <210> 155 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 15C6-A7 HVR-L1 <400> 155 Arg Ser Ser Gln Asn Ile Val His Ser Asn Gly Asn Thr Tyr Leu Glu 1 5 10 15 <210> 156 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 15C6-A7 HVR-L2 <400> 156 Lys Val Ser Asn Arg Phe Ser 1 5 <210> 157 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 15C6-A7 HVR-L3 <400> 157 Phe Gln Gly Ser His Val Pro Pro Thr 1 5 <210> 158 <400> 158 000 <210> 159 <400> 159 000 <210> 160 <211> 119 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 19F8-B1 heavy chain variable region (VH) <400> 160 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Tyr Met Lys Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 35 40 45 Gly Asp Leu Asn Pro Asn Asn Gly Gly Thr Leu Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Gln Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Phe Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ser Ala Gly Tyr Gly Asp Ser Phe Ala Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ala 115 <210> 161 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 19F8-B1 light chain variable region (VL) <400> 161 Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 1 5 10 15 Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Asn Ile Val His Ser 20 25 30 Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Leu Gly Ile Tyr Phe Cys Phe Gln Gly 85 90 95 Ser His Val Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 162 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 19F8-B1 HVR-H1 <400> 162 Asp Tyr Tyr Met Lys 1 5 <210> 163 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 19F8-B1 HVR-H2 <400> 163 Asp Leu Asn Pro Asn Asn Gly Gly Thr Leu Tyr Asn Gln Lys Phe Lys 1 5 10 15 Gly <210> 164 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 19F8-B1 HVR-H3 <400> 164 Ser Ala Gly Tyr Gly Asp Ser Phe Ala Tyr 1 5 10 <210> 165 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 19F8-B1 HVR-L1 <400> 165 Arg Ser Ser Gln Asn Ile Val His Ser Asn Gly Asn Thr Tyr Leu Glu 1 5 10 15 <210> 166 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 19F8-B1 HVR-L2 <400> 166 Lys Val Ser Asn Arg Phe Ser 1 5 <210> 167 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 19F8-B1 HVR-L3 <400> 167 Phe Gln Gly Ser His Val Pro Pro Thr 1 5 <210> 168 <400> 168 000 <210> 169 <400> 169 000 <210> 170 <211> 119 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 24A11-D5 heavy chain variable region (VH) <400> 170 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Tyr Met Lys Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile 35 40 45 Gly Asp Leu Asn Pro Lys Asn Gly Gly Ile Ile Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Gln Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Phe Tyr Cys 85 90 95 Ala Arg Ser Gly Gly Tyr Gly Asp Ser Phe Ala Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ala 115 <210> 171 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 24A11-D5 light chain variable region (VL) <400> 171 Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 1 5 10 15 Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Asn Ile Val His Ser 20 25 30 Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Leu Gly Ile Tyr Phe Cys Phe Gln Gly 85 90 95 Ser His Val Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 172 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 24A11-D5 HVR-H1 <400> 172 Asp Tyr Tyr Met Lys 1 5 <210> 173 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 24A11-D5 HVR-H2 <400> 173 Asp Leu Asn Pro Lys Asn Gly Gly Ile Ile Tyr Asn Gln Lys Phe Lys 1 5 10 15 Gly <210> 174 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 24A11-D5 HVR-H3 <400> 174 Ser Gly Gly Tyr Gly Asp Ser Phe Ala Tyr 1 5 10 <210> 175 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 24A11-D5 HVR-L1 <400> 175 Arg Ser Ser Gln Asn Ile Val His Ser Asn Gly Asn Thr Tyr Leu Glu 1 5 10 15 <210> 176 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 24A11-D5 HVR-L2 <400> 176 Lys Val Ser Asn Arg Phe Ser 1 5 <210> 177 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 24A11-D5 HVR-L3 <400> 177 Phe Gln Gly Ser His Val Pro Pro Thr 1 5 <210> 178 <400> 178 000 <210> 179 <400> 179 000 <210> 180 <211> 114 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 126F11-G11 heavy chain variable region (VH) <400> 180 Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Asp 20 25 30 Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 35 40 45 Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr Glu Tyr Ala Ser Lys Phe 50 55 60 Gln Gly Lys Ala Thr Ile Thr Thr Asp Thr Ser Ser Asn Thr Ala Tyr 65 70 75 80 Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Leu Asp Phe Ala Tyr Gly Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 100 105 110 Ser Ser <210> 181 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 126F11-G11 light chain variable region (VL) <400> 181 Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 1 5 10 15 Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser 20 25 30 Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Phe Gln Gly 85 90 95 Ser His Val Pro Pro Ala Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 182 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 126F11-G11 HVR-H1 <400> 182 Asp Asp Tyr Met His 1 5 <210> 183 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 126F11-G11 HVR-H2 <400> 183 Trp Ile Asp Pro Glu Asn Gly Asp Thr Glu Tyr Ala Ser Lys Phe Gln 1 5 10 15 Gly <210> 184 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 126F11-G11 HVR-H3 <400> 184 Phe Ala Tyr Gly Tyr 1 5 <210> 185 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 126F11-G11 HVR-L1 <400> 185 Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Asn Thr Tyr Leu Glu 1 5 10 15 <210> 186 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 126F11-G11 HVR-L2 <400> 186 Lys Val Ser Asn Arg Phe Ser 1 5 <210> 187 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 126F11-G11 HVR-L3 <400> 187 Phe Gln Gly Ser His Val Pro Pro Ala 1 5 <210> 188 <400> 188 000 <210> 189 <400> 189 000 <210> 190 <211> 120 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 89F4-A1 heavy chain variable region (VH) <400> 190 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Lys Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Thr Tyr 20 25 30 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Arg Ile Arg Ser Lys Ser Asn Asn Tyr Ala Ala Tyr Phe Ala Asp 50 55 60 Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Asp Asp Ser Gln Thr Met 65 70 75 80 Leu Tyr Leu Gln Met Asn Asn Leu Lys Ser Glu Asp Thr Ala Met Tyr 85 90 95 Tyr Cys Val Ser Gly Gly Asn Tyr Val Pro Phe Ala Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ala 115 120 <210> 191 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 89F4-A1 light chain variable region (VL) <400> 191 Asn Ile Met Met Thr Gln Ser Pro Ser Ser Leu Ala Val Ser Ala Gly 1 5 10 15 Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Val Phe Tyr Ser 20 25 30 Ser Glu Gln Arg Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 35 40 45 Ser Pro Lys Leu Leu Ile Ser Trp Ala Ser Thr Arg Glu Ser Gly Val 50 55 60 Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 65 70 75 80 Ile Ser Ser Val Gln Gly Glu Asp Leu Ala Val Tyr Tyr Cys His Gln 85 90 95 Tyr Leu Ser Ser Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 192 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 89F4-A1 HVR-H1 <400> 192 Thr Tyr Ala Met Asn 1 5 <210> 193 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 89F4-A1 HVR-H2 <400> 193 Arg Ile Arg Ser Lys Ser Asn Asn Tyr Ala Ala Tyr Phe Ala Asp Ser 1 5 10 15 Val Lys Asp <210> 194 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 89F4-A1 HVR-H3 <400> 194 Gly Gly Asn Tyr Val Pro Phe Ala Tyr 1 5 <210> 195 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 89F4-A1 HVR-L1 <400> 195 Lys Ser Ser Gln Ser Val Phe Tyr Ser Ser Glu Gln Arg Asn Tyr Leu 1 5 10 15 No <210> 196 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 89F4-A1 HVR-L2 <400> 196 Trp Ala Ser Thr Arg Glu Ser 1 5 <210> 197 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 89F4-A1 HVR-L3 <400> 197 His Gln Tyr Leu Ser Ser Phe Thr 1 5 <210> 198 <400> 198 000 <210> 199 <400> 199 000 <210> 200 <211> 115 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 93A8-D2 heavy chain variable region (VH) <400> 200 Glu Val Gln Leu Gln Gln Ser Gly Pro Val Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Tyr Val Asn Trp Val Lys Gln Ser His Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Leu Ile Asn Pro Asn Asn Gly Arg Thr Ser Tyr Asn Gln Asn Phe 50 55 60 Asn Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Phe 65 70 75 80 Met Asp Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Thr Arg Glu Gly Gly Thr Gly Tyr Trp Gly Gln Gly Thr Thr Leu Ser 100 105 110 Val Ser Ser 115 <210> 201 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 93A8-D2 light chain variable region (VL) <400> 201 Asp Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser Val Thr Ile Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser 20 25 30 Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser 35 40 45 Pro Arg Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro 50 55 60 Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Ala Ala Glu Asp Leu Gly Val Tyr Tyr Cys Trp Gln Gly 85 90 95 Thr His Phe Pro Arg Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 202 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 93A8-D2 HVR-H1 <400> 202 Asp Tyr Tyr Val Asn 1 5 <210> 203 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 93A8-D2 HVR-H2 <400> 203 Leu Ile Asn Pro Asn Asn Gly Arg Thr Ser Tyr Asn Gln Asn Phe Asn 1 5 10 15 Asp <210> 204 <211> 6 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 93A8-D2 HVR-H3 <400> 204 Glu Gly Gly Thr Gly Tyr 1 5 <210> 205 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 93A8-D2 HVR-L1 <400> 205 Lys Ser Ser Gln Ser Leu Leu Asp Ser Asp Gly Lys Thr Tyr Leu Asn 1 5 10 15 <210> 206 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 93A8-D2 HVR-L2 <400> 206 Leu Val Ser Lys Leu Asp Ser 1 5 <210> 207 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 93A8-D2 HVR-L3 <400> 207 Trp Gln Gly Thr His Phe Pro Arg Thr 1 5 <210> 208 <400> 208 000 <210> 209 <400> 209 000 <210> 210 <211> 120 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 14F5-D9 heavy chain variable region (VH) <400> 210 Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Phe Thr Phe Ser Asp Phe 20 25 30 Tyr Met Glu Trp Val Arg Gln Ser Pro Gly Lys Arg Leu Glu Trp Ile 35 40 45 Ala Ala Ser Lys Asn Lys Ala Asn Asp Tyr Thr Thr Glu Tyr Asn Ala 50 55 60 Ser Val Lys Asp Arg Phe Phe Val Ser Arg Asp Thr Ser Gln Ser Ile 65 70 75 80 Leu Tyr Leu Gln Met Asn Ala Leu Arg Ala Glu Asp Thr Ala Ile Tyr 85 90 95 Tyr Cys Ala Arg Asp Ala Leu Gly Thr Val Phe Ala Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ala 115 120 <210> 211 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 14F5-D9 light chain variable region (VL) <400> 211 Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 1 5 10 15 Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser 20 25 30 Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Lys Leu Leu Ile Tyr Lys Val Phe Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser 85 90 95 Thr Leu Val Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 100 105 110 <210> 212 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 14F5-D9 HVR-H1 <400> 212 Asp Phe Tyr Met Glu 1 5 <210> 213 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 14F5-D9 HVR-H2 <400> 213 Ala Ser Lys Asn Lys Ala Asn Asp Tyr Thr Thr Glu Tyr Asn Ala Ser 1 5 10 15 Val Lys Asp <210> 214 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 14F5-D9 HVR-H3 <400> 214 Asp Ala Leu Gly Thr Val Phe Ala Tyr 1 5 <210> 215 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 14F5-D9 HVR-L1 <400> 215 Arg Ser Ser Gln Ser Leu Val His Ser Asn Gly Asn Thr Tyr Leu His 1 5 10 15 <210> 216 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 14F5-D9 HVR-L2 <400> 216 Lys Val Phe Asn Arg Phe Ser 1 5 <210> 217 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 14F5-D9 HVR-L3 <400> 217 Ser Gln Ser Thr Leu Val Pro Leu Thr 1 5 <210> 218 <400> 218 000 <210> 219 <400> 219 000 <210> 220 <211> 122 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 73H6-B8 heavy chain variable region (VH) <400> 220 Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln 1 5 10 15 Ser Leu Ser Ile Thr Cys Thr Ile Ser Gly Phe Ser Leu Thr Ser Tyr 20 25 30 Gly Val His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu 35 40 45 Val Val Ile Trp Ser Asp Gly Ser Thr Thr Tyr Asn Ser Ala Leu Lys 50 55 60 Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe Leu 65 70 75 80 Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Met Tyr Tyr Cys Ala 85 90 95 Arg Gln Gly Gly Phe Ile Thr Thr Ala Tyr Tyr Ala Met Asp Tyr Trp 100 105 110 Gly Gln Gly Thr Ser Val Thr Val Ser Ser 115 120 <210> 221 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 73H6-B8 light chain variable region (VL) <400> 221 Asp Ile Val Met Ser Gln Ser Pro Ser Ser Leu Ala Val Ser Ala Gly 1 5 10 15 Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser 20 25 30 Arg Thr Arg Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 35 40 45 Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 50 55 60 Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 65 70 75 80 Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Lys Gln 85 90 95 Ser Tyr Asn Leu Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 222 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 73H6-B8 HVR-H1 <400> 222 Ser Tyr Gly Val His 1 5 <210> 223 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 73H6-B8 HVR-H2 <400> 223 Val Ile Trp Ser Asp Gly Ser Thr Thr Tyr Asn Ser Ala Leu Lys Ser 1 5 10 15 <210> 224 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 73H6-B8 HVR-H3 <400> 224 Gln Gly Gly Phe Ile Thr Thr Ala Tyr Tyr Ala Met Asp Tyr 1 5 10 <210> 225 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 73H6-B8 HVR-L1 <400> 225 Lys Ser Ser Gln Ser Leu Leu Asn Ser Arg Thr Arg Lys Asn Tyr Leu 1 5 10 15 Ala <210> 226 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 73H6-B8 HVR-L2 <400> 226 Trp Ala Ser Thr Arg Glu Ser 1 5 <210> 227 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 73H6-B8 HVR-L3 <400> 227 Lys Gln Ser Tyr Asn Leu Tyr Thr 1 5 <210> 228 <400> 228 000 <210> 229 <400> 229 000 <210> 230 <211> 120 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 22G7-C9 heavy chain variable region (VH) <400> 230 Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Cys 20 25 30 Ser Ile His Trp Val Lys Gln Ala Pro Gly Glu Gly Leu Lys Trp Met 35 40 45 Gly Trp Ile Asn Thr Glu Thr Gly Glu Pro Ser Tyr Ala Asp Asp Phe 50 55 60 Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Phe 65 70 75 80 Leu Gln Ile Asn Asn Leu Lys Ser Glu Asp Thr Ala Ser Tyr Phe Cys 85 90 95 Gly Thr Ala Tyr Tyr Arg Tyr Asp Gly Ala Leu Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Ser Val Thr Val Ser Ser 115 120 <210> 231 <211> 111 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 22G7-C9 light chain variable region (VL) <400> 231 Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly 1 5 10 15 Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Ser 20 25 30 Ser Tyr Ser Tyr Met His Trp Phe Gln Gln Lys Pro Gly Gln Pro Pro 35 40 45 Lys Leu Leu Ile Lys Tyr Ala Ser Asn Leu Glu Ser Gly Val Pro Ala 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His 65 70 75 80 Pro Val Glu Glu Glu Asp Thr Ala Thr Tyr Tyr Cys Gln His Ser Trp 85 90 95 Glu Leu Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 232 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 22G7-C9 HVR-H1 <400> 232 Asp Cys Ser Ile His 1 5 <210> 233 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 22G7-C9 HVR-H2 <400> 233 Trp Ile Asn Thr Glu Thr Gly Glu Pro Ser Tyr Ala Asp Asp Phe Lys 1 5 10 15 Gly <210> 234 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 22G7-C9 HVR-H3 <400> 234 Ala Tyr Tyr Arg Tyr Asp Gly Ala Leu Asp Tyr 1 5 10 <210> 235 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 22G7-C9 HVR-L1 <400> 235 Arg Ala Ser Gln Ser Val Ser Thr Ser Ser Tyr Ser Tyr Met His 1 5 10 15 <210> 236 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 22G7-C9 HVR-L2 <400> 236 Tyr Ala Ser Asn Leu Glu Ser 1 5 <210> 237 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 22G7-C9 HVR-L3 <400> 237 Gln His Ser Trp Glu Leu Pro Trp Thr 1 5 <210> 238 <400> 238 000 <210> 239 <400> 239 000 <210> 240 <211> 116 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 7A11-C12 heavy chain variable region (VH) <400> 240 Gln Ile Gln Leu Val Gln Ser Gly Pro Asp Leu Lys Lys Pro Gly Glu 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 35 40 45 Gly Trp Ile Asn Thr Asn Thr Gly Glu Pro Thr Tyr Ala Glu Glu Phe 50 55 60 Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 65 70 75 80 Leu Gln Ile Asp Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 85 90 95 Ala Arg Gly Thr Val Ser Phe Pro Tyr Trp Gly Gln Gly Thr Leu Val 100 105 110 Thr Val Ser Ala 115 <210> 241 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 7A11-C12 light chain variable region (VL) <400> 241 Asp Val Val Met Ser Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 1 5 10 15 Asp His Ala Ser Ile Ser Cys Arg Ser Ser Gln Asn Leu Val His Ser 20 25 30 Asp Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser 85 90 95 Thr His Val Ile Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 242 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 7A11-C12 HVR-H1 <400> 242 Asn Tyr Gly Met Asn 1 5 <210> 243 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 7A11-C12 HVR-H2 <400> 243 Trp Ile Asn Thr Asn Thr Gly Glu Pro Thr Tyr Ala Glu Glu Phe Lys 1 5 10 15 Gly <210> 244 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 7A11-C12 HVR-H3 <400> 244 Gly Thr Val Ser Phe Pro Tyr 1 5 <210> 245 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 7A11-C12 HVR-L1 <400> 245 Arg Ser Ser Gln Asn Leu Val His Ser Asp Gly Asn Thr Tyr Leu His 1 5 10 15 <210> 246 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 7A11-C12 HVR-L2 <400> 246 Lys Val Ser Asn Arg Phe Ser 1 5 <210> 247 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 7A11-C12 HVR-L3 <400> 247 Ser Gln Ser Thr His Val Ile Phe Thr 1 5 <210> 248 <400> 248 000 <210> 249 <400> 249 000 <210> 250 <211> 115 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 12A10-E8 heavy chain variable region (VH) <400> 250 Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met 35 40 45 Gly Trp Ile Asn Met Tyr Thr Gly Glu Pro Thr Tyr Gly Asp Asp Phe 50 55 60 Lys Gly Arg Phe Val Phe Ser Leu Glu Thr Ser Val Ser Thr Val Tyr 65 70 75 80 Leu Gln Ile Asn Asn Leu Lys Lys Glu Asp Thr Ala Thr Phe Phe Cys 85 90 95 Ala Arg Gly Gly Arg Pro Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr 100 105 110 Val Ser Ser 115 <210> 251 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 12A10-E8 light chain variable region (VL) <400> 251 Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 1 5 10 15 Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser 20 25 30 Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Lys Leu Leu Ile Tyr Lys Val Phe Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Asn Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Leu Gln Gly 85 90 95 Ser His Val Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 252 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 12A10-E8 HVR-H1 <400> 252 Asn Tyr Gly Met Asn 1 5 <210> 253 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 12A10-E8 HVR-H2 <400> 253 Trp Ile Asn Met Tyr Thr Gly Glu Pro Thr Tyr Gly Asp Asp Phe Lys 1 5 10 15 Gly <210> 254 <211> 6 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 12A10-E8 HVR-H3 <400> 254 Gly Gly Arg Pro Asp Tyr 1 5 <210> 255 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 12A10-E8 HVR-L1 <400> 255 Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Asn Thr Tyr Leu Glu 1 5 10 15 <210> 256 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 1 2A10-E8 HVR-L2 <400> 256 Lys Val Phe Asn Arg Phe Ser 1 5 <210> 257 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 12A10-E8 HVR-L3 <400> 257 Leu Gln Gly Ser His Val Pro Tyr Thr 1 5 <210> 258 <400> 258 000 <210> 259 <400> 259 000 <210> 260 <211> 120 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 55E7-F11 heavy chain variable region (VH) <400> 260 Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Met Lys Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Trp Met Asn Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Ala Gln Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser 65 70 75 80 Val Tyr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Gly Ile Tyr 85 90 95 Tyr Cys Ala Gly Tyr Phe Tyr Gly Gly Tyr Phe Asp Val Trp Gly Thr 100 105 110 Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 261 <211> 108 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 55E7-F11 light chain variable region (VL) <400> 261 Glu Leu Val Leu Thr Gln Ser Pro Thr Thr Met Ala Ala Ser Pro Gly 1 5 10 15 Lys Lys Ile Thr Ile Thr Cys Ser Ala Ser Ser Ser Ile Ser Ser Asn 20 25 30 Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Phe Ser Pro Lys Leu Leu 35 40 45 Ile Tyr Arg Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Gly Thr Met Glu 65 70 75 80 Ala Glu Asp Val Ala Thr Tyr Tyr Cys Gln Gln Gly Ser Ser Leu Pro 85 90 95 Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 262 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 55E7-F11 HVR-H1 <400> 262 Asn Tyr Trp Met Asn 1 5 <210> 263 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 55E7-F11 HVR-H2 <400> 263 Gln Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu Ser 1 5 10 15 Val Lys Gly <210> 264 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 55E7-F11 HVR-H3 <400> 264 Tyr Phe Tyr Gly Gly Tyr Phe Asp Val 1 5 <210> 265 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 55E7-F11 HVR-L1 <400> 265 Ser Ala Ser Ser Ser Ile Ser Ser Asn Tyr Leu His 1 5 10 <210> 266 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 55E7-F11 HVR-L2 <400> 266 Arg Thr Ser Asn Leu Ala Ser 1 5 <210> 267 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 55E7-F11 HVR-L3 <400> 267 Gln Gln Gly Ser Ser Leu Pro Phe Thr 1 5 <210> 268 <400> 268 000 <210> 269 <400> 269 000 <210> 270 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 52F6-F11 heavy chain variable region (VH) <400> 270 Gln Val Gln Leu Gln Gln Ser Gly Thr Glu Leu Ala Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr His Tyr 20 25 30 Trp Met His Trp Ile Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Pro Thr Asn Asp Tyr Thr Lys Tyr Asn Gln Asn Phe 50 55 60 Arg Asp Lys Ala Thr Leu Thr Ala Asp Glu Ser Ser Asn Ser Ala Tyr 65 70 75 80 Met Gln Leu Asn Ser Leu Thr Tyr Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ala Gly Asn Arg Val Phe Asp Phe Trp Gly Gln Gly Thr Thr 100 105 110 Leu Thr Val Ser Ser 115 <210> 271 <211> 109 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 52F6-F11 light chain variable region (VL) <400> 271 Gln Ala Val Val Thr Gln Glu Ser Ala Leu Thr Thr Ser Pro Gly Glu 1 5 10 15 Thr Val Thr Leu Thr Cys Arg Ser Ser Thr Gly Ala Val Thr Thr Ser 20 25 30 Asn Phe Ala Asn Trp Val Gln Glu Lys Pro Asp His Leu Phe Thr Gly 35 40 45 Leu Ile Gly Gly Thr Asn Asn Arg Ala Pro Gly Val Pro Ala Arg Phe 50 55 60 Ser Gly Ser Leu Ile Gly Asp Lys Ala Ala Leu Thr Ile Thr Gly Ala 65 70 75 80 Gln Thr Glu Asp Glu Ala Ile Tyr Phe Cys Ala Leu Trp Tyr Ser Asn 85 90 95 Leu Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 272 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 52F6-F11 HVR-H1 <400> 272 His Tyr Trp Met His 1 5 <210> 273 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 52F6-F11 HVR-H2 <400> 273 Tyr Ile Tyr Pro Thr Asn Asp Tyr Thr Lys Tyr Asn Gln Asn Phe Arg 1 5 10 15 Asp <210> 274 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 52F6-F11 HVR-H3 <400> 274 Ala Gly Asn Arg Val Phe Asp Phe 1 5 <210> 275 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 52F6-F11 HVR-L1 <400> 275 Arg Ser Ser Thr Gly Ala Val Thr Thr Ser Asn Phe Ala Asn 1 5 10 <210> 276 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 52F6-F11 HVR-L2 <400> 276 Gly Thr Asn Asn Arg Ala Pro 1 5 <210> 277 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: 52F6-F11 HVR-L3 <400> 277 Ala Leu Trp Tyr Ser Asn Leu Trp Val 1 5 <210> 278 <400> 278 000 <210> 279 <400> 279 000 <210> 280 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v1 heavy chain variable region (VH) <400> 280 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Ile Phe Arg Ser Tyr 20 25 30 Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Thr Ile Asn Ser Gly Gly Thr Tyr Thr Tyr Tyr Pro Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Asn Ser Tyr Ser Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115 <210> 281 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v1 light chain variable region (VL) <400> 281 Glu Asp Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Gln Ser Ile Val His Ser 20 25 30 Asn Gly Asn Thr Tyr Phe Glu Trp Tyr Gln Gln Lys Pro Gly Lys Ser 35 40 45 Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile 65 70 75 80 Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly 85 90 95 Ser Leu Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 282 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v1 HVR-H1 <400> 282 Ser Tyr Gly Met Ser 1 5 <210> 283 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v1 HVR-H2 <400> 283 Thr Ile Asn Ser Gly Gly Thr Tyr Thr Tyr Tyr Pro Asp Ser Val Lys 1 5 10 15 Gly <210> 284 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v1 HVR-H3 <400> 284 Ser Tyr Ser Gly Ala Met Asp Tyr 1 5 <210> 285 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v1 HVR-L1 <400> 285 Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Asn Thr Tyr Phe Glu 1 5 10 15 <210> 286 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v1 HVR-L2 <400> 286 Lys Val Ser Asn Arg Phe Ser 1 5 <210> 287 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v1 HVR-L3 <400> 287 Phe Gln Gly Ser Leu Val Pro Trp Thr 1 5 <210> 288 <211> 447 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v1 IgG1 heavy chain <400> 288 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Ile Phe Arg Ser Tyr 20 25 30 Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Thr Ile Asn Ser Gly Gly Thr Tyr Thr Tyr Tyr Pro Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Asn Ser Tyr Ser Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu 115 120 125 Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys 130 135 140 Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser 145 150 155 160 Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser 165 170 175 Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser 180 185 190 Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn 195 200 205 Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His 210 215 220 Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val 225 230 235 240 Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 245 250 255 Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu 260 265 270 Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 275 280 285 Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser 290 295 300 Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys 305 310 315 320 Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile 325 330 335 Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 340 345 350 Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu 355 360 365 Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 370 375 380 Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 385 390 395 400 Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg 405 410 415 Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 420 425 430 His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 289 <211> 219 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v1 IgG1 light chain <400> 289 Glu Asp Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Gln Ser Ile Val His Ser 20 25 30 Asn Gly Asn Thr Tyr Phe Glu Trp Tyr Gln Gln Lys Pro Gly Lys Ser 35 40 45 Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile 65 70 75 80 Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly 85 90 95 Ser Leu Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 115 120 125 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 130 135 140 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 145 150 155 160 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 165 170 175 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 180 185 190 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 195 200 205 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 290 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v5 heavy chain variable region (VH) <400> 290 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Ile Phe Arg Ser Tyr 20 25 30 Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Thr Ile Asn Ser Gly Gly Thr Tyr Thr Tyr Tyr Pro Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Asn Ser Tyr Ser Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115 <210> 291 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v5 light chain variable region (VL) <400> 291 Glu Asp Val Leu Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser 20 25 30 Asn Gly Asn Thr Tyr Phe Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Phe Gln Gly 85 90 95 Ser Leu Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 292 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v5 HVR-H1 <400> 292 Ser Tyr Gly Met Ser 1 5 <210> 293 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v5 HVR-H2 <400> 293 Thr Ile Asn Ser Gly Gly Thr Tyr Thr Tyr Tyr Pro Asp Ser Val Lys 1 5 10 15 Gly <210> 294 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v5 HVR-H3 <400> 294 Ser Tyr Ser Gly Ala Met Asp Tyr 1 5 <210> 295 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v5 HVR-L1 <400> 295 Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Asn Thr Tyr Phe Glu 1 5 10 15 <210> 296 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v5 HVR-L2 <400> 296 Lys Val Ser Asn Arg Phe Ser 1 5 <210> 297 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v5 HVR-L3 <400> 297 Phe Gln Gly Ser Leu Val Pro Trp Thr 1 5 <210> 298 <400> 298 000 <210> 299 <400> 299 000 <210> 300 <211> 113 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu94B2.v105 heavy chain variable region (VH) <400> 300 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Leu Thr Gly Tyr 20 25 30 Thr Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Leu Ile Ser Pro Tyr Asn Gly Val Thr Ser Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Arg Ala Thr Leu Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gln Gly Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser 100 105 110 Ser <210> 301 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu94B2.v105 light chain variable region (VL) <400> 301 Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser 20 25 30 Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Gln Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Trp Gln Gly 85 90 95 Thr His Phe Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 302 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu94B2.v105 HVR-H1 <400> 302 Gly Tyr Thr Met Asn 1 5 <210> 303 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu94B2.v105 HVR-H2 <400> 303 Leu Ile Ser Pro Tyr Asn Gly Val Thr Ser Tyr Asn Gln Lys Phe Lys 1 5 10 15 Gly <210> 304 <211> 4 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu94B2.v105 HVR-H3 <400> 304 Gln Gly Ala Tyr 1 <210> 305 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu94B2.v105 HVR-L1 <400> 305 Lys Ser Ser Gln Ser Leu Leu Asp Ser Asp Gly Lys Thr Tyr Leu Asn 1 5 10 15 <210> 306 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu94B2.v105 HVR-L2 <400> 306 Leu Val Ser Lys Leu Asp Ser 1 5 <210> 307 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu94B2.v105 HVR-L3 <400> 307 Trp Gln Gly Thr His Phe Pro Trp Thr 1 5 <210> 308 <400> 308 000 <210> 309 <400> 309 000 <210> 310 <211> 115 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu125B11.v17 heavy chain variable region (VH) <400> 310 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Arg Phe Ile Phe Ser Asn Tyr 20 25 30 Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Gln Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 65 70 75 80 Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Thr Gly Gly Thr Thr Tyr Trp Gly Gln Gly Thr Leu Val Thr 100 105 110 Val Ser Ser 115 <210> 311 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu125B11.v17 light chain variable region (VH) <400> 311 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ser Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Ile Arg Tyr Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Phe Arg Thr Tyr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 312 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu125B11.v17 HVR-H1 <400> 312 Asn Tyr Trp Met Asn 1 5 <210> 313 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu125B11.v17 HVR-H2 <400> 313 Gln Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu Ser 1 5 10 15 Val Lys Gly <210> 314 <211> 4 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu125B11.v17 HVR-H3 <400> 314 Gly Thr Thr Tyr 1 <210> 315 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu125B11.v17 HVR-L1 <400> 315 Lys Ala Ser Gln Asn Val Gly Thr Ala Val Ala 1 5 10 <210> 316 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu125B11.v17 HVR-L2 <400> 316 Ser Ala Ser Ile Arg Tyr Thr 1 5 <210> 317 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu125B11.v17 HVR-L3 <400> 317 Gln Gln Phe Arg Thr Tyr Pro Tyr Thr 1 5 <210> 318 <400> 318 000 <210> 319 <400> 319 000 <210> 320 <211> 115 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu125B11.v26 heavy chain variable region (VH) <400> 320 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Arg Phe Ile Phe Ser Asn Tyr 20 25 30 Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Gln Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr 65 70 75 80 Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Thr Gly Gly Thr Thr Tyr Trp Gly Gln Gly Thr Leu Val Thr 100 105 110 Val Ser Ser 115 <210> 321 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu125B11.v26 light chain variable region (VH) <400> 321 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Ile Arg Tyr Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Phe Arg Thr Tyr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 322 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu125B11.v26 HVR-H1 <400> 322 Asn Tyr Trp Met Asn 1 5 <210> 323 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu125B11.v26 HVR-H2 <400> 323 Gln Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu Ser 1 5 10 15 Val Lys Gly <210> 324 <211> 4 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu125B11.v26 HVR-H3 <400> 324 Gly Thr Thr Tyr 1 <210> 325 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu125B11.v26 HVR-L1 <400> 325 Lys Ala Ser Gln Asn Val Gly Thr Ala Val Ala 1 5 10 <210> 326 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu125B11.v26 HVR-L2 <400> 326 Ser Ala Ser Ile Arg Tyr Thr 1 5 <210> 327 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu125B11.v26 HVR-L3 <400> 327 Gln Gln Phe Arg Thr Tyr Pro Tyr Thr 1 5 <210> 328 <400> 328 000 <210> 329 <400> 329 000 <210> 330 <211> 115 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu125B11.v28 heavy chain variable region (VH) <400> 330 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Arg Phe Ile Phe Ser Asn Tyr 20 25 30 Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Gln Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr 65 70 75 80 Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Thr Gly Gly Thr Thr Tyr Trp Gly Gln Gly Thr Leu Val Thr 100 105 110 Val Ser Ser 115 <210> 331 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu125B11.v28 light chain variable region (VH) <400> 331 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Ile Arg Tyr Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Phe Arg Thr Tyr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 332 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu125B11.v28 HVR-H1 <400> 332 Asn Tyr Trp Met Asn 1 5 <210> 333 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu125B11.v28 HVR-H2 <400> 333 Gln Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu Ser 1 5 10 15 Val Lys Gly <210> 334 <211> 4 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu125B11.v28 HVR-H3 <400> 334 Gly Thr Thr Tyr 1 <210> 335 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu125B11.v28 HVR-L1 <400> 335 Lys Ala Ser Gln Asn Val Gly Thr Ala Val Ala 1 5 10 <210> 336 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu125B11.v28 HVR-L2 <400> 336 Ser Ala Ser Ile Arg Tyr Thr 1 5 <210> 337 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu125B11.v28 HVR-L3 <400> 337 Gln Gln Phe Arg Thr Tyr Pro Tyr Thr 1 5 <210> 338 <400> 338 000 <210> 339 <400> 339 000 <210> 340 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v28.A4 heavy chain variable region (VH) <400> 340 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Ile Phe Arg Ser Tyr 20 25 30 Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Thr Ile Asn Ser Gly Gly Thr Tyr Thr Tyr Tyr Pro Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Asn Ser Tyr Ser Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115 <210> 341 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v28.A4 light chain variable region (VL) <400> 341 Asp Asp Val Leu Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser 20 25 30 Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Phe Gln Gly 85 90 95 Ser Leu Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 342 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v28.A4 HVR-H1 <400> 342 Ser Tyr Gly Met Ser 1 5 <210> 343 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v28.A4 HVR-H2 <400> 343 Thr Ile Asn Ser Gly Gly Thr Tyr Thr Tyr Tyr Pro Asp Ser Val Lys 1 5 10 15 Gly <210> 344 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v28.A4 HVR-H3 <400> 344 Ser Tyr Ser Gly Ala Met Asp Tyr 1 5 <210> 345 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v28.A4 HVR-L1 <400> 345 Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Asn Thr Tyr Leu Glu 1 5 10 15 <210> 346 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v28.A4 HVR-L2 <400> 346 Lys Val Ser Asn Arg Phe Ser 1 5 <210> 347 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v28.A4 HVR-L3 <400> 347 Phe Gln Gly Ser Leu Val Pro Trp Thr 1 5 <210> 348 <211> 444 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v28.A4 IgG4-S228P.YTE heavy chain <400> 348 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Ile Phe Arg Ser Tyr 20 25 30 Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Thr Ile Asn Ser Gly Gly Thr Tyr Thr Tyr Tyr Pro Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Asn Ser Tyr Ser Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu 115 120 125 Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys 130 135 140 Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser 145 150 155 160 Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser 165 170 175 Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser 180 185 190 Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn 195 200 205 Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro 210 215 220 Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe 225 230 235 240 Pro Pro Lys Pro Lys Asp Thr Leu Tyr Ile Thr Arg Glu Pro Glu Val 245 250 255 Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe 260 265 270 Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro 275 280 285 Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 290 295 300 Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 305 310 315 320 Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala 325 330 335 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln 340 345 350 Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly 355 360 365 Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro 370 375 380 Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser 385 390 395 400 Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu 405 410 415 Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 420 425 430 Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys 435 440 <210> 349 <211> 219 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v28.A4 IgG4-S228P.YTE light chain <400> 349 Asp Asp Val Leu Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser 20 25 30 Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Phe Gln Gly 85 90 95 Ser Leu Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 115 120 125 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 130 135 140 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 145 150 155 160 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 165 170 175 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 180 185 190 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 195 200 205 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 350 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Unstressed control (mean, n=9) <400> 350 Glu Asp Leu His Ser Asn Gly Asn Thr Tyr Phe Leu 1 5 10 <210> 351 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3-H9.v5 <400> 351 Glu Asp Leu His Ser Asn Gly Asn Thr Tyr Phe Leu 1 5 10 <210> 352 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3-H9.v5.1 <400> 352 Glu Asp Leu His Ser Asn Ala Asn Thr Tyr Phe Leu 1 5 10 <210> 353 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3-H9.v5.2 <400> 353 Glu Asp Leu His Ser Ser Gly Asn Thr Tyr Phe Leu 1 5 10 <210> 354 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3-H9.v5.3 <400> 354 Glu Asp Leu His Ser Asp Gly Asn Thr Tyr Phe Leu 1 5 10 <210> 355 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3-H9.v5.4 <400> 355 Glu Asp Leu His Ser Gln Gly Asn Thr Tyr Phe Leu 1 5 10 <210> 356 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3-H9.v5.5 <400> 356 Glu Asp Leu His Ser Glu Gly Asn Thr Tyr Phe Leu 1 5 10 <210> 357 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3-H9.v5.6 <400> 357 Glu Asp Leu His Ser Ala Gly Asn Thr Tyr Phe Leu 1 5 10 <210> 358 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3-H9.v5.7 <400> 358 Glu Asp Leu His Ser Asn Gly Asp Thr Tyr Phe Leu 1 5 10 <210> 359 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3-H9.v5.8 <400> 359 Glu Asp Leu His Ser Asn Gly Gln Thr Tyr Phe Leu 1 5 10 <210> 360 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3-H9.v5.9 <400> 360 Glu Asp Leu His Ser Asn Gly Glu Thr Tyr Phe Leu 1 5 10 <210> 361 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3-H9.v5.10 <400> 361 Glu Asp Leu His Ser Asn Gly Ala Thr Tyr Phe Leu 1 5 10 <210> 362 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3-H9.v5.11 <400> 362 Glu Asp Leu His Ser Asn Gly Ser Thr Tyr Phe Leu 1 5 10 <210> 363 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v28 <400> 363 Asp Asp Leu His Ser Asn Gly Asn Thr Tyr Phe Leu 1 5 10 <210> 364 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v28.A2 <400> 364 Asp Asp Leu His Ser Asn Gly Asn Thr Tyr Phe His 1 5 10 <210> 365 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v28.A4 <400> 365 Asp Asp Leu His Ser Asn Gly Asn Thr Tyr Leu Leu 1 5 10 <210> 366 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v28.A6 <400> 366 Asp Asp Leu His Ser Asn Gly Asn Thr Tyr Leu His 1 5 10 <210> 367 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v28.A8 <400> 367 Asp Asp Met His Ser Asn Gly Asn Thr Tyr Phe Leu 1 5 10 <210> 368 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v28.A10 <400> 368 Asp Asp Met His Ser Asn Gly Asn Thr Tyr Phe His 1 5 10 <210> 369 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v28.A12 <400> 369 Asp Asp Met His Ser Asn Gly Asn Thr Tyr Leu Leu 1 5 10 <210> 370 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v28.A14 <400> 370 Asp Asp Met His Ser Asn Gly Asn Thr Tyr Leu His 1 5 10 <210> 371 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v28.A16 <400> 371 Asp Val Leu His Ser Asn Gly Asn Thr Tyr Phe Leu 1 5 10 <210> 372 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v28.A18 <400> 372 Asp Val Leu His Ser Asn Gly Asn Thr Tyr Phe His 1 5 10 <210> 373 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v28.A20 <400> 373 Asp Val Leu His Ser Asn Gly Asn Thr Tyr Leu Leu 1 5 10 <210> 374 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v28.A22 <400> 374 Asp Val Leu His Ser Asn Gly Asn Thr Tyr Leu His 1 5 10 <210> 375 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v28.A24 <400> 375 Asp Val Met His Ser Asn Gly Asn Thr Tyr Phe Leu 1 5 10 <210> 376 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v28.A26 <400> 376 Asp Val Met His Ser Asn Gly Asn Thr Tyr Phe His 1 5 10 <210> 377 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v28.A28 <400> 377 Asp Val Met His Ser Asn Gly Asn Thr Tyr Leu Leu 1 5 10 <210> 378 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v28.A30 <400> 378 Asp Val Met His Ser Asn Gly Asn Thr Tyr Leu His 1 5 10 <210> 379 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v28.B1 <400> 379 Asp Asp Leu His Ser Ile Gly Asn Thr Phe Phe Leu 1 5 10 <210> 380 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v28.B2 <400> 380 Asp Asp Leu His Ser Met Gly Asn Thr Phe Phe Leu 1 5 10 <210> 381 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v28.B3 <400> 381 Asp Asp Leu His Ser Gln Gly Asn Thr Trp Phe Leu 1 5 10 <210> 382 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v28.B4 <400> 382 Asp Asp Leu His Ser Gln Gly Asn Thr His Phe Leu 1 5 10 <210> 383 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v28.B6 <400> 383 Asp Asp Leu His Ser Asp Gly Asn Thr Arg Phe Leu 1 5 10 <210> 384 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v28.B7 <400> 384 Asp Asp Leu His Ser Asp Gly Asn Thr Lys Phe Leu 1 5 10 <210> 385 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v28.B8 <400> 385 Asp Asp Leu His Ser Glu Gly Asn Thr Arg Phe Leu 1 5 10 <210> 386 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v28.C1 <400> 386 Asp Asp Leu His Ser Asn Asn Asn Thr Tyr Phe Leu 1 5 10 <210> 387 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v28.C2 <400> 387 Asp Asp Leu His Ser Asn Asp Asn Thr Tyr Phe Leu 1 5 10 <210> 388 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v28.D1 <400> 388 Asp Asp Leu His Ala Asn Gly Asn Thr Tyr Phe Leu 1 5 10 <210> 389 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Unstressed control (mean, n=9) <400> 389 Glu Asp Leu His Ser Asn Gly Asn Thr Tyr Phe Leu 1 5 10 <210> 390 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v28.E1 <400> 390 Asp Asp Leu Asn Ser Asn Gly Asn Thr Tyr Phe Leu 1 5 10 <210> 391 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v28.E2 <400> 391 Asp Asp Leu Gln Ser Asn Gly Asn Thr Tyr Phe Leu 1 5 10 <210> 392 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v28.E3 <400> 392 Asp Asp Leu Asp Ser Asp Gly Asn Thr Tyr Phe Leu 1 5 10 <210> 393 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v28.F1 <400> 393 Asp Asp Leu His Ser Asn Thr Asn Thr Tyr Phe Leu 1 5 10 <210> 394 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v28.F2 <400> 394 Asp Asp Leu His Thr Asn Gly Asn Thr Tyr Phe Leu 1 5 10 <210> 395 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v28.F3 <400> 395 Asp Asp Leu His Thr Asn Ala Asn Thr Tyr Phe Leu 1 5 10 <210> 396 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v28.51 <400> 396 Glu Asp Leu His Ser His Gly Asn Thr Tyr Phe Leu 1 5 10 <210> 397 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v28.52 <400> 397 Glu Asp Leu His Ser Lys Gly Asn Thr Tyr Phe Leu 1 5 10 <210> 398 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v28.53 <400> 398 Glu Asp Leu His Ser Arg Gly Asn Thr Tyr Phe Leu 1 5 10 <210> 399 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v28.54 <400> 399 Glu Asp Leu His Ser Leu Gly Asn Thr Tyr Phe Leu 1 5 10 <210> 400 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v28.55 <400> 400 Asp Asp Leu His Ser Asn Gln Asn Thr Tyr Phe Leu 1 5 10 <210> 401 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v28.56 <400> 401 Asp Asp Leu His Ser Asn Tyr Asn Thr Tyr Phe Leu 1 5 10 <210> 402 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v28.57 <400> 402 Asp Asp Leu His Ser Asn Phe Asn Thr Tyr Phe Leu 1 5 10 <210> 403 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v29.1 <400> 403 Glu Asp Leu His Ser Asn Gly Asp Thr Tyr Phe Leu 1 5 10 <210> 404 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v29.2 <400> 404 Glu Asp Leu His Ser Asn Gly Gln Thr Tyr Phe Leu 1 5 10 <210> 405 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v29.3 <400> 405 Glu Asp Leu His Ser Asn Gly Glu Thr Tyr Phe Leu 1 5 10 <210> 406 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v29.4 <400> 406 Glu Asp Leu His Ser Asn Gly Ala Thr Tyr Phe Leu 1 5 10 <210> 407 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v29.5 <400> 407 Glu Asp Leu His Ser Asn Gly His Thr Tyr Phe Leu 1 5 10 <210> 408 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v29.6 <400> 408 Glu Asp Leu His Ser Asn Gly Lys Thr Tyr Phe Leu 1 5 10 <210> 409 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v29.7 <400> 409 Glu Asp Leu His Ser Asn Gly Leu Thr Tyr Phe Leu 1 5 10 <210> 410 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v29.8 <400> 410 Glu Asp Leu His Ser Asn Ala Asp Thr Tyr Phe Leu 1 5 10 <210> 411 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v29.9 <400> 411 Glu Asp Leu His Ser Asn Ala Gln Thr Tyr Phe Leu 1 5 10 <210> 412 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v29.10 <400> 412 Glu Asp Leu His Ser Asn Ala Glu Thr Tyr Phe Leu 1 5 10 <210> 413 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v29.11 <400> 413 Glu Asp Leu His Ser Asn Ala Ala Thr Tyr Phe Leu 1 5 10 <210> 414 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v29.12 <400> 414 Glu Asp Leu His Ser Asn Ala His Thr Tyr Phe Leu 1 5 10 <210> 415 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v29.13 <400> 415 Glu Asp Leu His Ser Asn Ala Lys Thr Tyr Phe Leu 1 5 10 <210> 416 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3.v29.14 <400> 416 Glu Asp Leu His Ser Asn Ala Leu Thr Tyr Phe Leu 1 5 10 <210> 417 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3-H9.v30.1 <400> 417 Asp Asp Leu His Ser Gly Gly Asn Thr Tyr Phe Leu 1 5 10 <210> 418 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3-H9.v30.2 <400> 418 Asp Asp Leu His Ser Thr Gly Asn Thr Tyr Phe Leu 1 5 10 <210> 419 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3-H9.v30.3 <400> 419 Asp Asp Leu His Ser Val Gly Asn Thr Tyr Phe Leu 1 5 10 <210> 420 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3-H9.v30.4 <400> 420 Asp Asp Leu His Ser Leu Gly Asn Thr Tyr Phe Leu 1 5 10 <210> 421 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3-H9.v30.5 <400> 421 Asp Asp Leu His Ser Ile Gly Asn Thr Tyr Phe Leu 1 5 10 <210> 422 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3-H9.v30.6 <400> 422 Asp Asp Leu His Ser Pro Gly Asn Thr Tyr Phe Leu 1 5 10 <210> 423 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3-H9.v30.7 <400> 423 Asp Asp Leu His Ser Phe Gly Asn Thr Tyr Phe Leu 1 5 10 <210> 424 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3-H9.v30.8 <400> 424 Asp Asp Leu His Ser Tyr Gly Asn Thr Tyr Phe Leu 1 5 10 <210> 425 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3-H9.v30.9 <400> 425 Asp Asp Leu His Ser His Gly Asn Thr Tyr Phe Leu 1 5 10 <210> 426 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3-H9.v30.10 <400> 426 Asp Asp Leu His Ser Lys Gly Asn Thr Tyr Phe Leu 1 5 10 <210> 427 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3-H9.v30.11 <400> 427 Asp Asp Leu His Ser Arg Gly Asn Thr Tyr Phe Leu 1 5 10 <210> 428 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3-H9.v31.1 <400> 428 Asp Asp Leu His Ser Asn Ala Gly Thr Tyr Phe Leu 1 5 10 <210> 429 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3-H9.v31.2 <400> 429 Asp Asp Leu His Ser Asn Ala Val Thr Tyr Phe Leu 1 5 10 <210> 430 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3-H9.v31.3 <400> 430 Asp Asp Leu His Ser Asn Ala Ile Thr Tyr Phe Leu 1 5 10 <210> 431 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3-H9.v31.4 <400> 431 Asp Asp Leu His Ser Asn Ala Pro Thr Tyr Phe Leu 1 5 10 <210> 432 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3-H9.v31.5 <400> 432 Asp Asp Leu His Ser Asn Ala Phe Thr Tyr Phe Leu 1 5 10 <210> 433 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3-H9.v31.6 <400> 433 Asp Asp Leu His Ser Asn Ala Tyr Thr Tyr Phe Leu 1 5 10 <210> 434 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3-H9.v31.7 <400> 434 Asp Asp Leu His Ser Asn Ala Arg Thr Tyr Phe Leu 1 5 10 <210> 435 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3-H9.v31.8 <400> 435 Asp Asp Leu His Ser Asn Ala Asn Val Tyr Phe Leu 1 5 10 <210> 436 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3-H9.v31.9 <400> 436 Asp Asp Leu His Ser Asn Ala Asn Ile Tyr Phe Leu 1 5 10 <210> 437 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3-H9.v31.10 <400> 437 Asp Asp Leu His Ser Asn Ala Asn Pro Tyr Phe Leu 1 5 10 <210> 438 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3-H9.v31.11 <400> 438 Asp Asp Leu His Ser Asn Ala Asn Phe Tyr Phe Leu 1 5 10 <210> 439 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3-H9.v31.12 <400> 439 Asp Asp Leu His Ser Asn Ala Asn Tyr Tyr Phe Leu 1 5 10 <210> 440 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3-H9.v31.13 <400> 440 Asp Asp Leu His Ser Asn Ala Asn Asn Tyr Phe Leu 1 5 10 <210> 441 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu37D3-H9.v31.14 <400> 441 Asp Asp Leu His Ser Asn Ala Asn Arg Tyr Phe Leu 1 5 10 <210> 442 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu125B11-H3.LC1 <400> 442 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ser Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Ile Arg Tyr Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Phe Arg Thr Tyr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 443 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu125B11-H3.LC2 <400> 443 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Ile Arg Tyr Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Phe Arg Thr Tyr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 444 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu125B11-H3.LC3 <400> 444 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ser Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Ile Arg Tyr Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Phe Arg Thr Tyr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 445 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu125B11-H3.LC4 <400> 445 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Ile Arg Tyr Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Phe Arg Thr Tyr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 446 <211> 115 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu125B11-H3.HC1 <400> 446 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Arg Phe Ile Phe Ser Asn Tyr 20 25 30 Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Gln Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 65 70 75 80 Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Thr Gly Gly Thr Thr Tyr Trp Gly Gln Gly Thr Leu Val Thr 100 105 110 Val Ser Ser 115 <210> 447 <211> 115 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu125B11-H3.HC2 <400> 447 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Arg Phe Ile Phe Ser Asn Tyr 20 25 30 Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Gln Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr 65 70 75 80 Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Thr Gly Gly Thr Thr Tyr Trp Gly Gln Gly Thr Leu Val Thr 100 105 110 Val Ser Ser 115 <210> 448 <211> 115 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu125B11-H3.HC3 <400> 448 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Arg Phe Ile Phe Ser Asn Tyr 20 25 30 Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Gln Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 65 70 75 80 Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Thr Gly Gly Thr Thr Tyr Trp Gly Gln Gly Thr Leu Val Thr 100 105 110 Val Ser Ser 115 <210> 449 <211> 115 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu125B11-H3.HC4 <400> 449 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Arg Phe Ile Phe Ser Asn Tyr 20 25 30 Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Gln Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr 65 70 75 80 Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Thr Gly Gly Thr Thr Tyr Trp Gly Gln Gly Thr Leu Val Thr 100 105 110 Val Ser Ser 115 <210> 450 <211> 115 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu125B11-H3.HC5 <400> 450 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Arg Phe Ile Phe Ser Asn Tyr 20 25 30 Tyr Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Gln Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 65 70 75 80 Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Thr Gly Gly Thr Thr Tyr Trp Gly Gln Gly Thr Leu Val Thr 100 105 110 Val Ser Ser 115 <210> 451 <211> 115 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu125B11-H3.HC6 <400> 451 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Arg Phe Ile Phe Ser Asn Tyr 20 25 30 Phe Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Gln Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr 65 70 75 80 Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr 85 90 95 Tyr Cys Thr Gly Gly Thr Thr Tyr Trp Gly Gln Gly Thr Leu Val Thr 100 105 110 Val Ser Ser 115 <210> 452 <211> 113 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu94B2.HC1 <400> 452 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Leu Thr Gly Tyr 20 25 30 Thr Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Leu Ile Ser Pro Tyr Asn Gly Val Thr Ser Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Arg Ala Thr Leu Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gln Gly Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser 100 105 110 Ser <210> 453 <211> 113 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu94B2.HC2 <400> 453 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Leu Thr Gly Tyr 20 25 30 Thr Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Leu Ile Ser Pro Tyr Asn Gly Val Thr Ser Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Arg Val Thr Leu Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gln Gly Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser 100 105 110 Ser <210> 454 <211> 113 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu94B2.HC3 <400> 454 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Leu Thr Gly Tyr 20 25 30 Thr Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Leu Ile Ser Pro Tyr Asn Gly Val Thr Ser Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Arg Ala Thr Ile Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gln Gly Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser 100 105 110 Ser <210> 455 <211> 113 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu94B2.HC4 <400> 455 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Leu Thr Gly Tyr 20 25 30 Thr Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Leu Ile Ser Pro Tyr Asn Gly Val Thr Ser Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Arg Ala Thr Leu Thr Arg Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gln Gly Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser 100 105 110 Ser <210> 456 <211> 113 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu94B2.HC5 <400> 456 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Leu Thr Gly Tyr 20 25 30 Thr Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Leu Ile Ser Pro Tyr Asn Gly Val Thr Ser Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Arg Ala Thr Leu Thr Val Asp Thr Ser Thr Ser Thr Ala Tyr 65 70 75 80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gln Gly Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser 100 105 110 Looking <210> 457 <211> 113 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu94B2.HC6 <400> 457 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Leu Thr Gly Tyr 20 25 30 Thr Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Leu Ile Ser Pro Tyr Asn Gly Val Thr Ser Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Arg Val Thr Ile Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gln Gly Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser 100 105 110 Ser <210> 458 <211> 113 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu94B2.HC7 <400> 458 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Leu Thr Gly Tyr 20 25 30 Thr Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Leu Ile Ser Pro Tyr Asn Gly Val Thr Ser Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Arg Val Thr Ile Thr Arg Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gln Gly Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser 100 105 110 Ser <210> 459 <211> 113 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu94B2.HC8 <400> 459 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Leu Thr Gly Tyr 20 25 30 Thr Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Leu Ile Ser Pro Tyr Asn Gly Val Thr Ser Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Arg Val Thr Ile Thr Val Asp Thr Ser Thr Ser Thr Ala Tyr 65 70 75 80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gln Gly Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser 100 105 110 Ser <210> 460 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu94B2.LC9 <400> 460 Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser 20 25 30 Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Gln Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Trp Gln Gly 85 90 95 Thr His Phe Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 461 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu94B2.LC10 <400> 461 Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser 20 25 30 Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Trp Gln Gly 85 90 95 Thr His Phe Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 462 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu94B2.LC11 <400> 462 Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser 20 25 30 Asp Gly Lys Thr Tyr Leu Asn Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Gln Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Trp Gln Gly 85 90 95 Thr His Phe Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 463 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu94B2.LC12 <400> 463 Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser 20 25 30 Asp Gly Lys Thr Tyr Leu Asn Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Trp Gln Gly 85 90 95 Thr His Phe Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 464 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu94B2.LC13 <400> 464 Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser 20 25 30 Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Gln Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Trp Gln Gly 85 90 95 Thr His Phe Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 465 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu94B2.LC14 <400> 465 Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser 20 25 30 Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Trp Gln Gly 85 90 95 Thr His Phe Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 466 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu94B2.LC15 <400> 466 Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser 20 25 30 Asp Gly Lys Thr Tyr Leu Asn Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Gln Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Trp Gln Gly 85 90 95 Thr His Phe Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 467 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu94B2.LC16 <400> 467 Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser 20 25 30 Asp Gly Lys Thr Tyr Leu Asn Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Trp Gln Gly 85 90 95 Thr His Phe Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 468 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v5.1 HVR-L1 <400> 468 Arg Ser Ser Gln Ser Ile Val His Ser Asn Ala Asn Thr Tyr Phe Glu 1 5 10 15 <210> 469 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v5.2 HVR-L1 <400> 469 Arg Ser Ser Gln Ser Ile Val His Ser Ser Gly Asn Thr Tyr Phe Glu 1 5 10 15 <210> 470 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v5.3 HVR-L1 <400> 470 Arg Ser Ser Gln Ser Ile Val His Ser Asp Gly Asn Thr Tyr Phe Glu 1 5 10 15 <210> 471 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v5.4 HVR-L1 <400> 471 Arg Ser Ser Gln Ser Ile Val His Ser Gln Gly Asn Thr Tyr Phe Glu 1 5 10 15 <210> 472 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v5.5 HVR-L1 <400> 472 Arg Ser Ser Gln Ser Ile Val His Ser Glu Gly Asn Thr Tyr Phe Glu 1 5 10 15 <210> 473 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v5.6 HVR-L1 <400> 473 Arg Ser Ser Gln Ser Ile Val His Ser Ala Gly Asn Thr Tyr Phe Glu 1 5 10 15 <210> 474 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v5.7 HVR-L1 <400> 474 Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Asp Thr Tyr Phe Glu 1 5 10 15 <210> 475 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v5.8 HVR-L1 <400> 475 Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Gln Thr Tyr Phe Glu 1 5 10 15 <210> 476 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v5.9 HVR-L1 <400> 476 Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Glu Thr Tyr Phe Glu 1 5 10 15 <210> 477 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v5.10 HVR-L1 <400> 477 Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Ala Thr Tyr Phe Glu 1 5 10 15 <210> 478 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v5.11 HVR-L1 <400> 478 Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Ser Thr Tyr Phe Glu 1 5 10 15 <210> 479 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v28 HVR-L1 <400> 479 Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Asn Thr Tyr Phe Glu 1 5 10 15 <210> 480 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v28.A2 HVR-L1 <400> 480 Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Asn Thr Tyr Phe Glu 1 5 10 15 <210> 481 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v28.A4 HVR-L1 <400> 481 Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Asn Thr Tyr Leu Glu 1 5 10 15 <210> 482 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v28.A6 HVR-L1 <400> 482 Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Asn Thr Tyr Leu Glu 1 5 10 15 <210> 483 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v28.A8 HVR-L1 <400> 483 Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Asn Thr Tyr Phe Glu 1 5 10 15 <210> 484 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v28.A10 HVR-L1 <400> 484 Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Asn Thr Tyr Phe Glu 1 5 10 15 <210> 485 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v28.A12 HVR-L1 <400> 485 Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Asn Thr Tyr Leu Glu 1 5 10 15 <210> 486 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v28.A14 HVR-L1 <400> 486 Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Asn Thr Tyr Leu Glu 1 5 10 15 <210> 487 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v28.A16 HVR-L1 <400> 487 Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Asn Thr Tyr Phe Glu 1 5 10 15 <210> 488 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v28.A18 HVR-L1 <400> 488 Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Asn Thr Tyr Phe Glu 1 5 10 15 <210> 489 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v28.A20 HVR-L1 <400> 489 Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Asn Thr Tyr Leu Glu 1 5 10 15 <210> 490 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v28.A22 HVR-L1 <400> 490 Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Asn Thr Tyr Leu Glu 1 5 10 15 <210> 491 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v28.A24 HVR-L1 <400> 491 Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Asn Thr Tyr Phe Glu 1 5 10 15 <210> 492 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v28.A26 HVR-L1 <400> 492 Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Asn Thr Tyr Phe Glu 1 5 10 15 <210> 493 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v28.A28 HVR-L1 <400> 493 Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Asn Thr Tyr Leu Glu 1 5 10 15 <210> 494 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v28.A30 HVR-L1 <400> 494 Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Asn Thr Tyr Leu Glu 1 5 10 15 <210> 495 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v28.B1 HVR-L1 <400> 495 Arg Ser Ser Gln Ser Ile Val His Ser Ile Gly Asn Thr Phe Phe Glu 1 5 10 15 <210> 496 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v28.B2 HVR-L1 <400> 496 Arg Ser Ser Gln Ser Ile Val His Ser Met Gly Asn Thr Phe Phe Glu 1 5 10 15 <210> 497 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v28.B3 HVR-L1 <400> 497 Arg Ser Ser Gln Ser Ile Val His Ser Gln Gly Asn Thr Trp Phe Glu 1 5 10 15 <210> 498 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v28.B4 HVR-L1 <400> 498 Arg Ser Ser Gln Ser Ile Val His Ser Gln Gly Asn Thr His Phe Glu 1 5 10 15 <210> 499 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v28.B6 HVR-L1 <400> 499 Arg Ser Ser Gln Ser Ile Val His Ser Asp Gly Asn Thr Arg Phe Glu 1 5 10 15 <210> 500 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v28.B7 HVR-L1 <400> 500 Arg Ser Ser Gln Ser Ile Val His Ser Asp Gly Asn Thr Lys Phe Glu 1 5 10 15 <210> 501 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v28.B8 HVR-L1 <400> 501 Arg Ser Ser Gln Ser Ile Val His Ser Glu Gly Asn Thr Arg Phe Glu 1 5 10 15 <210> 502 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v28.C1 HVR-L1 <400> 502 Arg Ser Ser Gln Ser Ile Val His Ser Asn Asn Asn Thr Tyr Phe Glu 1 5 10 15 <210> 503 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v28.C2 HVR-L1 <400> 503 Arg Ser Ser Gln Ser Ile Val His Ser Asn Asp Asn Thr Tyr Phe Glu 1 5 10 15 <210> 504 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v28.D1 HVR-L1 <400> 504 Arg Ser Ser Gln Ser Ile Val His Ala Asn Gly Asn Thr Tyr Phe Glu 1 5 10 15 <210> 505 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v28.E1 HVR-L1 <400> 505 Arg Ser Ser Gln Ser Ile Val Asn Ser Asn Gly Asn Thr Tyr Phe Glu 1 5 10 15 <210> 506 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v28.E2 HVR-L1 <400> 506 Arg Ser Ser Gln Ser Ile Val Gln Ser Asn Gly Asn Thr Tyr Phe Glu 1 5 10 15 <210> 507 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v28.E3 HVR-L1 <400> 507 Arg Ser Ser Gln Ser Ile Val Asp Ser Asp Gly Asn Thr Tyr Phe Glu 1 5 10 15 <210> 508 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v28.F1 HVR-L1 <400> 508 Arg Ser Ser Gln Ser Ile Val His Ser Asn Thr Asn Thr Tyr Phe Glu 1 5 10 15 <210> 509 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v28.F2 HVR-L1 <400> 509 Arg Ser Ser Gln Ser Ile Val His Thr Asn Gly Asn Thr Tyr Phe Glu 1 5 10 15 <210> 510 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v28.F3 HVR-L1 <400> 510 Arg Ser Ser Gln Ser Ile Val His Thr Asn Ala Asn Thr Tyr Phe Glu 1 5 10 15 <210> 511 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v28.51 HVR-L1 <400> 511 Arg Ser Ser Gln Ser Ile Val His Ser His Gly Asn Thr Tyr Phe Glu 1 5 10 15 <210> 512 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v28.52 HVR-L1 <400> 512 Arg Ser Ser Gln Ser Ile Val His Ser Lys Gly Asn Thr Tyr Phe Glu 1 5 10 15 <210> 513 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v28.53 HVR-L1 <400> 513 Arg Ser Ser Gln Ser Ile Val His Ser Arg Gly Asn Thr Tyr Phe Glu 1 5 10 15 <210> 514 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v28.54 HVR-L1 <400> 514 Arg Ser Ser Gln Ser Ile Val His Ser Leu Gly Asn Thr Tyr Phe Glu 1 5 10 15 <210> 515 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v28.55 HVR-L1 <400> 515 Arg Ser Ser Gln Ser Ile Val His Ser Asn Gln Asn Thr Tyr Phe Glu 1 5 10 15 <210> 516 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v28.56 HVR-L1 <400> 516 Arg Ser Ser Gln Ser Ile Val His Ser Asn Tyr Asn Thr Tyr Phe Glu 1 5 10 15 <210> 517 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v28.57 HVR-L1 <400> 517 Arg Ser Ser Gln Ser Ile Val His Ser Asn Phe Asn Thr Tyr Phe Glu 1 5 10 15 <210> 518 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v29.1 HVR-L1 <400> 518 Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Asp Thr Tyr Phe Glu 1 5 10 15 <210> 519 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v29.2 HVR-L1 <400> 519 Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Gln Thr Tyr Phe Glu 1 5 10 15 <210> 520 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v29.3 HVR-L1 <400> 520 Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Glu Thr Tyr Phe Glu 1 5 10 15 <210> 521 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v29.4 HVR-L1 <400> 521 Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Ala Thr Tyr Phe Glu 1 5 10 15 <210> 522 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v29.5 HVR-L1 <400> 522 Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly His Thr Tyr Phe Glu 1 5 10 15 <210> 523 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v29.6 HVR-L1 <400> 523 Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Lys Thr Tyr Phe Glu 1 5 10 15 <210> 524 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v29.7 HVR-L1 <400> 524 Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Leu Thr Tyr Phe Glu 1 5 10 15 <210> 525 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v29.8 HVR-L1 <400> 525 Arg Ser Ser Gln Ser Ile Val His Ser Asn Ala Asp Thr Tyr Phe Glu 1 5 10 15 <210> 526 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v29.9 HVR-L1 <400> 526 Arg Ser Ser Gln Ser Ile Val His Ser Asn Ala Gln Thr Tyr Phe Glu 1 5 10 15 <210> 527 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v29.10 HVR-L1 <400> 527 Arg Ser Ser Gln Ser Ile Val His Ser Asn Ala Glu Thr Tyr Phe Glu 1 5 10 15 <210> 528 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v29.11 HVR-L1 <400> 528 Arg Ser Ser Gln Ser Ile Val His Ser Asn Ala Ala Thr Tyr Phe Glu 1 5 10 15 <210> 529 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v29.12 HVR-L1 <400> 529 Arg Ser Ser Gln Ser Ile Val His Ser Asn Ala His Thr Tyr Phe Glu 1 5 10 15 <210> 530 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v29.13 HVR-L1 <400> 530 Arg Ser Ser Gln Ser Ile Val His Ser Asn Ala Lys Thr Tyr Phe Glu 1 5 10 15 <210> 531 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v29.14 HVR-L1 <400> 531 Arg Ser Ser Gln Ser Ile Val His Ser Asn Ala Leu Thr Tyr Phe Glu 1 5 10 15 <210> 532 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v30.1 HVR-L1 <400> 532 Arg Ser Ser Gln Ser Ile Val His Ser Gly Gly Asn Thr Tyr Phe Glu 1 5 10 15 <210> 533 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v30.2 HVR-L1 <400> 533 Arg Ser Ser Gln Ser Ile Val His Ser Thr Gly Asn Thr Tyr Phe Glu 1 5 10 15 <210> 534 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v30.3 HVR-L1 <400> 534 Arg Ser Ser Gln Ser Ile Val His Ser Val Gly Asn Thr Tyr Phe Glu 1 5 10 15 <210> 535 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v30.4 HVR-L1 <400> 535 Arg Ser Ser Gln Ser Ile Val His Ser Leu Gly Asn Thr Tyr Phe Glu 1 5 10 15 <210> 536 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v30.5 HVR-L1 <400> 536 Arg Ser Ser Gln Ser Ile Val His Ser Ile Gly Asn Thr Tyr Phe Glu 1 5 10 15 <210> 537 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v30.6 HVR-L1 <400> 537 Arg Ser Ser Gln Ser Ile Val His Ser Pro Gly Asn Thr Tyr Phe Glu 1 5 10 15 <210> 538 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v30.7 HVR-L1 <400> 538 Arg Ser Ser Gln Ser Ile Val His Ser Phe Gly Asn Thr Tyr Phe Glu 1 5 10 15 <210> 539 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v30.8 HVR-L1 <400> 539 Arg Ser Ser Gln Ser Ile Val His Ser Tyr Gly Asn Thr Tyr Phe Glu 1 5 10 15 <210> 540 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v30.9 HVR-L1 <400> 540 Arg Ser Ser Gln Ser Ile Val His Ser His Gly Asn Thr Tyr Phe Glu 1 5 10 15 <210> 541 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v30.10 HVR-L1 <400> 541 Arg Ser Ser Gln Ser Ile Val His Ser Lys Gly Asn Thr Tyr Phe Glu 1 5 10 15 <210> 542 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v30.11 HVR-L1 <400> 542 Arg Ser Ser Gln Ser Ile Val His Ser Arg Gly Asn Thr Tyr Phe Glu 1 5 10 15 <210> 543 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v31.1 HVR-L1 <400> 543 Arg Ser Ser Gln Ser Ile Val His Ser Asn Ala Gly Thr Tyr Phe Glu 1 5 10 15 <210> 544 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v31.2 HVR-L1 <400> 544 Arg Ser Ser Gln Ser Ile Val His Ser Asn Ala Val Thr Tyr Phe Glu 1 5 10 15 <210> 545 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v31.3 HVR-L1 <400> 545 Arg Ser Ser Gln Ser Ile Val His Ser Asn Ala Ile Thr Tyr Phe Glu 1 5 10 15 <210> 546 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v31.4 HVR-L1 <400> 546 Arg Ser Ser Gln Ser Ile Val His Ser Asn Ala Pro Thr Tyr Phe Glu 1 5 10 15 <210> 547 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v31.5 HVR-L1 <400> 547 Arg Ser Ser Gln Ser Ile Val His Ser Asn Ala Phe Thr Tyr Phe Glu 1 5 10 15 <210> 548 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v31.6 HVR-L1 <400> 548 Arg Ser Ser Gln Ser Ile Val His Ser Asn Ala Tyr Thr Tyr Phe Glu 1 5 10 15 <210> 549 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v31.7 HVR-L1 <400> 549 Arg Ser Ser Gln Ser Ile Val His Ser Asn Ala Arg Thr Tyr Phe Glu 1 5 10 15 <210> 550 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v31.8 HVR-L1 <400> 550 Arg Ser Ser Gln Ser Ile Val His Ser Asn Ala Asn Val Tyr Phe Glu 1 5 10 15 <210> 551 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v31.9 HVR-L1 <400> 551 Arg Ser Ser Gln Ser Ile Val His Ser Asn Ala Asn Ile Tyr Phe Glu 1 5 10 15 <210> 552 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v31.10 HVR-L1 <400> 552 Arg Ser Ser Gln Ser Ile Val His Ser Asn Ala Asn Pro Tyr Phe Glu 1 5 10 15 <210> 553 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v31.11 HVR-L1 <400> 553 Arg Ser Ser Gln Ser Ile Val His Ser Asn Ala Asn Phe Tyr Phe Glu 1 5 10 15 <210> 554 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v31.12 HVR-L1 <400> 554 Arg Ser Ser Gln Ser Ile Val His Ser Asn Ala Asn Tyr Tyr Phe Glu 1 5 10 15 <210> 555 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v31.13 HVR-L1 <400> 555 Arg Ser Ser Gln Ser Ile Val His Ser Asn Ala Asn Asn Tyr Phe Glu 1 5 10 15 <210> 556 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v31.14 HVR-L1 <400> 556 Arg Ser Ser Gln Ser Ile Val His Ser Asn Ala Asn Arg Tyr Phe Glu 1 5 10 15 <210> 557 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Human Tau 7-24 peptide <400> 557 Glu Phe Glu Val Met Glu Asp His Ala Gly Thr Tyr Gly Leu Gly Asp 1 5 10 15 Arg Lys <210> 558 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Human Tau 7-20 peptide <400> 558 Glu Phe Glu Val Met Glu Asp His Ala Gly Thr Tyr Gly Leu 1 5 10 <210> 559 <400> 559 000 <210> 560 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v39 heavy chain variable region (VH) <400> 560 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Ile Phe Arg Ser Tyr 20 25 30 Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Thr Ile Asn Ser Gly Gly Thr Tyr Thr Tyr Tyr Pro Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Asn Ser Tyr Ser Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115 <210> 561 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v39 light chain variable region (VL) <400> 561 Glu Asp Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Gln Ser Ile Val His Ser 20 25 30 Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Gln Gln Lys Pro Gly Lys Ser 35 40 45 Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile 65 70 75 80 Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly 85 90 95 Ser Leu Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 562 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v39 HVR-H1 <400> 562 Ser Tyr Gly Met Ser 1 5 <210> 563 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v39 HVR-H2 <400> 563 Thr Ile Asn Ser Gly Gly Thr Tyr Thr Tyr Tyr Pro Asp Ser Val Lys 1 5 10 15 Gly <210> 564 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v39 HVR-H3 <400> 564 Ser Tyr Ser Gly Ala Met Asp Tyr 1 5 <210> 565 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v39 HVR-L1 <400> 565 Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Asn Thr Tyr Leu Glu 1 5 10 15 <210> 566 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v39 HVR-L2 <400> 566 Lys Val Ser Asn Arg Phe Ser 1 5 <210> 567 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v39 HVR-L3 <400> 567 Phe Gln Gly Ser Leu Val Pro Trp Thr 1 5 <210> 568 <211> 444 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v39 IgG4-S228P.YTE heavy chain <400> 568 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Ile Phe Arg Ser Tyr 20 25 30 Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Thr Ile Asn Ser Gly Gly Thr Tyr Thr Tyr Tyr Pro Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Asn Ser Tyr Ser Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu 115 120 125 Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys 130 135 140 Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser 145 150 155 160 Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser 165 170 175 Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser 180 185 190 Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn 195 200 205 Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro 210 215 220 Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe 225 230 235 240 Pro Pro Lys Pro Lys Asp Thr Leu Tyr Ile Thr Arg Glu Pro Glu Val 245 250 255 Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe 260 265 270 Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro 275 280 285 Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 290 295 300 Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 305 310 315 320 Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala 325 330 335 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln 340 345 350 Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly 355 360 365 Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro 370 375 380 Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser 385 390 395 400 Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu 405 410 415 Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 420 425 430 Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys 435 440 <210> 569 <211> 219 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v39 IgG4-S228P.YTE light chain <400> 569 Glu Asp Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Gln Ser Ile Val His Ser 20 25 30 Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Gln Gln Lys Pro Gly Lys Ser 35 40 45 Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile 65 70 75 80 Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly 85 90 95 Ser Leu Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 115 120 125 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 130 135 140 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 145 150 155 160 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 165 170 175 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 180 185 190 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 195 200 205 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 570 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v40 heavy chain variable region (VH) <400> 570 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Ile Phe Arg Ser Tyr 20 25 30 Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Thr Ile Asn Ser Gly Gly Thr Tyr Thr Tyr Tyr Pro Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Asn Ser Tyr Ser Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115 <210> 571 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v40 light chain variable region (VL) <400> 571 Glu Asp Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Gln Ser Ile Val His Ser 20 25 30 Asn Thr Asn Thr Tyr Phe Glu Trp Tyr Gln Gln Lys Pro Gly Lys Ser 35 40 45 Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile 65 70 75 80 Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly 85 90 95 Ser Leu Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 572 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v40 HVR-H1 <400> 572 Ser Tyr Gly Met Ser 1 5 <210> 573 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v40 HVR-H2 <400> 573 Thr Ile Asn Ser Gly Gly Thr Tyr Thr Tyr Tyr Pro Asp Ser Val Lys 1 5 10 15 Gly <210> 574 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v40 HVR-H3 <400> 574 Ser Tyr Ser Gly Ala Met Asp Tyr 1 5 <210> 575 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v40 HVR-L1 <400> 575 Arg Ser Ser Gln Ser Ile Val His Ser Asn Thr Asn Thr Tyr Phe Glu 1 5 10 15 <210> 576 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v40 HVR-L2 <400> 576 Lys Val Ser Asn Arg Phe Ser 1 5 <210> 577 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v40 HVR-L3 <400> 577 Phe Gln Gly Ser Leu Val Pro Trp Thr 1 5 <210> 578 <211> 444 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v40 IgG4-S228P.YTE heavy chain <400> 578 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Ile Phe Arg Ser Tyr 20 25 30 Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Thr Ile Asn Ser Gly Gly Thr Tyr Thr Tyr Tyr Pro Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Asn Ser Tyr Ser Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu 115 120 125 Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys 130 135 140 Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser 145 150 155 160 Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser 165 170 175 Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser 180 185 190 Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn 195 200 205 Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro 210 215 220 Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe 225 230 235 240 Pro Pro Lys Pro Lys Asp Thr Leu Tyr Ile Thr Arg Glu Pro Glu Val 245 250 255 Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe 260 265 270 Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro 275 280 285 Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 290 295 300 Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 305 310 315 320 Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala 325 330 335 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln 340 345 350 Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly 355 360 365 Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro 370 375 380 Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser 385 390 395 400 Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu 405 410 415 Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 420 425 430 Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys 435 440 <210> 579 <211> 219 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v40 IgG4-S228P.YTE light chain <400> 579 Glu Asp Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Gln Ser Ile Val His Ser 20 25 30 Asn Thr Asn Thr Tyr Phe Glu Trp Tyr Gln Gln Lys Pro Gly Lys Ser 35 40 45 Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile 65 70 75 80 Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly 85 90 95 Ser Leu Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 115 120 125 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 130 135 140 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 145 150 155 160 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 165 170 175 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 180 185 190 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 195 200 205 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 580 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v41 heavy chain variable region (VH) <400> 580 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Ile Phe Arg Ser Tyr 20 25 30 Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Thr Ile Asn Ser Gly Gly Thr Tyr Thr Tyr Tyr Pro Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Asn Ser Tyr Ser Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115 <210> 581 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v41 light chain variable region (VL) <400> 581 Glu Asp Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Gln Ser Ile Val His Ser 20 25 30 Asn Gly Gln Thr Tyr Phe Glu Trp Tyr Gln Gln Lys Pro Gly Lys Ser 35 40 45 Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile 65 70 75 80 Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly 85 90 95 Ser Leu Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 582 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v41 HVR-H1 <400> 582 Ser Tyr Gly Met Ser 1 5 <210> 583 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v41 HVR-H2 <400> 583 Thr Ile Asn Ser Gly Gly Thr Tyr Thr Tyr Tyr Pro Asp Ser Val Lys 1 5 10 15 Gly <210> 584 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v41 HVR-H3 <400> 584 Ser Tyr Ser Gly Ala Met Asp Tyr 1 5 <210> 585 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v41 HVR-L1 <400> 585 Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Gln Thr Tyr Phe Glu 1 5 10 15 <210> 586 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v41 HVR-L2 <400> 586 Lys Val Ser Asn Arg Phe Ser 1 5 <210> 587 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v41 HVR-L3 <400> 587 Phe Gln Gly Ser Leu Val Pro Trp Thr 1 5 <210> 588 <211> 444 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v41 IgG4-S228P.YTE heavy chain <400> 588 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Ile Phe Arg Ser Tyr 20 25 30 Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Thr Ile Asn Ser Gly Gly Thr Tyr Thr Tyr Tyr Pro Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Asn Ser Tyr Ser Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu 115 120 125 Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys 130 135 140 Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser 145 150 155 160 Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser 165 170 175 Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser 180 185 190 Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn 195 200 205 Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro 210 215 220 Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe 225 230 235 240 Pro Pro Lys Pro Lys Asp Thr Leu Tyr Ile Thr Arg Glu Pro Glu Val 245 250 255 Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe 260 265 270 Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro 275 280 285 Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 290 295 300 Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 305 310 315 320 Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala 325 330 335 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln 340 345 350 Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly 355 360 365 Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro 370 375 380 Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser 385 390 395 400 Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu 405 410 415 Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 420 425 430 Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys 435 440 <210> 589 <211> 219 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3.v41 IgG4-S228P.YTE light chain <400> 589 Glu Asp Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Gln Ser Ile Val His Ser 20 25 30 Asn Gly Gln Thr Tyr Phe Glu Trp Tyr Gln Gln Lys Pro Gly Lys Ser 35 40 45 Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile 65 70 75 80 Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly 85 90 95 Ser Leu Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 115 120 125 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 130 135 140 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 145 150 155 160 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 165 170 175 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 180 185 190 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 195 200 205 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 590 <211> 444 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v1 IgG4 heavy chain <400> 590 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Ile Phe Arg Ser Tyr 20 25 30 Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Thr Ile Asn Ser Gly Gly Thr Tyr Thr Tyr Tyr Pro Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Asn Ser Tyr Ser Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu 115 120 125 Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys 130 135 140 Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser 145 150 155 160 Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser 165 170 175 Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser 180 185 190 Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn 195 200 205 Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro 210 215 220 Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe 225 230 235 240 Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val 245 250 255 Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe 260 265 270 Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro 275 280 285 Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 290 295 300 Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 305 310 315 320 Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala 325 330 335 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln 340 345 350 Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly 355 360 365 Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro 370 375 380 Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser 385 390 395 400 Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu 405 410 415 Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 420 425 430 Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys 435 440 <210> 591 <211> 219 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v1 IgG4 light chain <400> 591 Glu Asp Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Gln Ser Ile Val His Ser 20 25 30 Asn Gly Asn Thr Tyr Phe Glu Trp Tyr Gln Gln Lys Pro Gly Lys Ser 35 40 45 Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile 65 70 75 80 Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly 85 90 95 Ser Leu Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 115 120 125 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 130 135 140 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 145 150 155 160 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 165 170 175 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 180 185 190 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 195 200 205 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 592 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: MAPT(10-24) <400> 592 Val Met Glu Asp His Ala Gly Thr Tyr Gly Leu Gly Asp Arg Lys 1 5 10 15 <210> 593 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: MAPT(2-24) <400> 593 Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly Thr 1 5 10 15 Tyr Gly Leu Gly Asp Arg Lys 20 <210> 594 <211> 33 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: MAPT(2-34) <400> 594 Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly Thr 1 5 10 15 Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His Gln 20 25 30 Asp <210> 595 <211> 35 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: MAPT(10-44) <400> 595 Val Met Glu Asp His Ala Gly Thr Tyr Gly Leu Gly Asp Arg Lys Asp 1 5 10 15 Gln Gly Gly Tyr Thr Met His Gln Asp Gln Glu Gly Asp Thr Asp Ala 20 25 30 Gly Leu Lys 35 <210> 596 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: MAPT(2-24)Y18A <400> 596 Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly Thr 1 5 10 15 Ala Gly Leu Gly Asp Arg Lys 20 <210> 597 <211> 23 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: MAPT(2-24)L20A <400> 597 Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly Thr 1 5 10 15 Tyr Gly Ala Gly Asp Arg Lys 20 <210> 598 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu113F5-F7.LC1 <400> 598 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ser Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Arg Arg Phe Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Phe Ser Thr Tyr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 599 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu113F5-F7.LC2 <400> 599 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Arg Arg Phe Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Phe Ser Thr Tyr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 600 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu113F5-F7.LC3 <400> 600 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ser Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Arg Arg Phe Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Phe Ser Thr Tyr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 601 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: hu113F5-F7.LC4 <400> 601 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Arg Arg Phe Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Phe Ser Thr Tyr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 602 <211> 443 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v28.A4 IgG4-S228P.YTE des-K heavy chain <400> 602 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Ile Phe Arg Ser Tyr 20 25 30 Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Thr Ile Asn Ser Gly Gly Thr Tyr Thr Tyr Tyr Pro Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Asn Ser Tyr Ser Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu 115 120 125 Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys 130 135 140 Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser 145 150 155 160 Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser 165 170 175 Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser 180 185 190 Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn 195 200 205 Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro 210 215 220 Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe 225 230 235 240 Pro Pro Lys Pro Lys Asp Thr Leu Tyr Ile Thr Arg Glu Pro Glu Val 245 250 255 Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe 260 265 270 Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro 275 280 285 Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 290 295 300 Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 305 310 315 320 Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala 325 330 335 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln 340 345 350 Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly 355 360 365 Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro 370 375 380 Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser 385 390 395 400 Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu 405 410 415 Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 420 425 430 Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly 435 440 <210> 603 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v76 heavy chain variable region (VH) <400> 603 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Ile Phe Arg Ser Tyr 20 25 30 Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Thr Ile Asn Ser Gly Gly Thr Arg Thr Tyr Tyr Pro Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Asn Ser Tyr Ser Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115 <210> 604 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v76 light chain variable region (VL) <400> 604 Asp Asp Leu Leu Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser 20 25 30 Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Phe Gln Gly 85 90 95 Thr Leu Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 605 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v76 HVR-H1; Hu37D3-H9.v83 HVR-H1; Hu37D3-H9.v93 HVR-H1 <400> 605 Ser Tyr Gly Met Ser 1 5 <210> 606 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v76 HVR-H2; Hu37D3-H9.v83 HVR-H2; Hu37D3-H9.v93 HVR-H2 <400> 606 Thr Ile Asn Ser Gly Gly Thr Arg Thr Tyr Tyr Pro Asp Ser Val Lys 1 5 10 15 Gly <210> 607 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v76 HVR-H3; Hu37D3-H9.v83 HVR-H3; Hu37D3-H9.v93 HVR-H3 <400> 607 Ser Tyr Ser Gly Ala Met Asp Tyr 1 5 <210> 608 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v76 HVR-L1; Hu37D3-H9.v83 HVR-L1; Hu37D3-H9.v93 HVR-L1 <400> 608 Arg Ser Ser Gln Ser Ile Val His Ser Asn Gly Asn Thr Tyr Leu Glu 1 5 10 15 <210> 609 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v76 HVR-L2; Hu37D3-H9.v83 HVR-L2; Hu37D3-H9.v93 HVR-L2 <400> 609 Lys Val Ser Asn Arg Phe Ser 1 5 <210> 610 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v76 HVR-L3; Hu37D3-H9.v83 HVR-L3; Hu37D3-H9.v93 HVR-L3 <400> 610 Phe Gln Gly Thr Leu Val Pro Trp Thr 1 5 <210> 611 <211> 444 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v76 IgG4-S228P.YTE heavy chain <400> 611 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Ile Phe Arg Ser Tyr 20 25 30 Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Thr Ile Asn Ser Gly Gly Thr Arg Thr Tyr Tyr Pro Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Asn Ser Tyr Ser Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu 115 120 125 Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys 130 135 140 Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser 145 150 155 160 Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser 165 170 175 Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser 180 185 190 Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn 195 200 205 Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro 210 215 220 Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe 225 230 235 240 Pro Pro Lys Pro Lys Asp Thr Leu Tyr Ile Thr Arg Glu Pro Glu Val 245 250 255 Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe 260 265 270 Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro 275 280 285 Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 290 295 300 Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 305 310 315 320 Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala 325 330 335 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln 340 345 350 Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly 355 360 365 Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro 370 375 380 Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser 385 390 395 400 Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu 405 410 415 Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 420 425 430 Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys 435 440 <210> 612 <211> 443 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v76 IgG4-S228P.YTE des-K heavy chain <400> 612 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Ile Phe Arg Ser Tyr 20 25 30 Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Thr Ile Asn Ser Gly Gly Thr Arg Thr Tyr Tyr Pro Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Asn Ser Tyr Ser Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu 115 120 125 Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys 130 135 140 Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser 145 150 155 160 Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser 165 170 175 Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser 180 185 190 Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn 195 200 205 Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro 210 215 220 Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe 225 230 235 240 Pro Pro Lys Pro Lys Asp Thr Leu Tyr Ile Thr Arg Glu Pro Glu Val 245 250 255 Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe 260 265 270 Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro 275 280 285 Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 290 295 300 Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 305 310 315 320 Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala 325 330 335 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln 340 345 350 Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly 355 360 365 Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro 370 375 380 Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser 385 390 395 400 Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu 405 410 415 Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 420 425 430 Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly 435 440 <210> 613 <211> 219 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v76 IgG4-S228P.YTE light chain <400> 613 Asp Asp Leu Leu Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser 20 25 30 Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Phe Gln Gly 85 90 95 Thr Leu Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 115 120 125 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 130 135 140 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 145 150 155 160 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 165 170 175 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 180 185 190 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 195 200 205 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 614 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v83 heavy chain variable region (VH) <400> 614 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Ile Phe Arg Ser Tyr 20 25 30 Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Thr Ile Asn Ser Gly Gly Thr Arg Thr Tyr Tyr Pro Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Asn Ser Tyr Ser Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115 <210> 615 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v83 light chain variable region (VL) <400> 615 Asp Asp Leu Leu Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser 20 25 30 Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Gln Gln Arg Pro Gly Gln Ser 35 40 45 Pro Arg Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Phe Gln Gly 85 90 95 Thr Leu Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 616 <211> 444 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v83 IgG4-S228P.YTE heavy chain <400> 616 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Ile Phe Arg Ser Tyr 20 25 30 Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Thr Ile Asn Ser Gly Gly Thr Arg Thr Tyr Tyr Pro Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Asn Ser Tyr Ser Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu 115 120 125 Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys 130 135 140 Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser 145 150 155 160 Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser 165 170 175 Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser 180 185 190 Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn 195 200 205 Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro 210 215 220 Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe 225 230 235 240 Pro Pro Lys Pro Lys Asp Thr Leu Tyr Ile Thr Arg Glu Pro Glu Val 245 250 255 Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe 260 265 270 Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro 275 280 285 Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 290 295 300 Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 305 310 315 320 Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala 325 330 335 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln 340 345 350 Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly 355 360 365 Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro 370 375 380 Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser 385 390 395 400 Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu 405 410 415 Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 420 425 430 Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys 435 440 <210> 617 <211> 443 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v83 IgG4-S228P.YTE des-K heavy chain <400> 617 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Ile Phe Arg Ser Tyr 20 25 30 Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Thr Ile Asn Ser Gly Gly Thr Arg Thr Tyr Tyr Pro Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Asn Ser Tyr Ser Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu 115 120 125 Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys 130 135 140 Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser 145 150 155 160 Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser 165 170 175 Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser 180 185 190 Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn 195 200 205 Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro 210 215 220 Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe 225 230 235 240 Pro Pro Lys Pro Lys Asp Thr Leu Tyr Ile Thr Arg Glu Pro Glu Val 245 250 255 Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe 260 265 270 Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro 275 280 285 Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 290 295 300 Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 305 310 315 320 Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala 325 330 335 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln 340 345 350 Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly 355 360 365 Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro 370 375 380 Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser 385 390 395 400 Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu 405 410 415 Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 420 425 430 Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly 435 440 <210> 618 <211> 219 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v83 IgG4-S228P.YTE light chain <400> 618 Asp Asp Leu Leu Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser 20 25 30 Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Gln Gln Arg Pro Gly Gln Ser 35 40 45 Pro Arg Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Phe Gln Gly 85 90 95 Thr Leu Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 115 120 125 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 130 135 140 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 145 150 155 160 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 165 170 175 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 180 185 190 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 195 200 205 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 619 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v93 heavy chain variable region (VH) <400> 619 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Ile Phe Arg Ser Tyr 20 25 30 Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Thr Ile Asn Ser Gly Gly Thr Arg Thr Tyr Tyr Pro Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Asn Ser Tyr Ser Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115 <210> 620 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v93 light chain variable region (VL) <400> 620 Glu Asp Leu Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Gln Ser Ile Val His Ser 20 25 30 Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Gln Gln Lys Pro Gly Lys Ser 35 40 45 Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile 65 70 75 80 Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly 85 90 95 Thr Leu Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 621 <211> 444 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v93 IgG4-S228P.YTE heavy chain <400> 621 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Ile Phe Arg Ser Tyr 20 25 30 Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Thr Ile Asn Ser Gly Gly Thr Arg Thr Tyr Tyr Pro Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Asn Ser Tyr Ser Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu 115 120 125 Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys 130 135 140 Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser 145 150 155 160 Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser 165 170 175 Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser 180 185 190 Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn 195 200 205 Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro 210 215 220 Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe 225 230 235 240 Pro Pro Lys Pro Lys Asp Thr Leu Tyr Ile Thr Arg Glu Pro Glu Val 245 250 255 Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe 260 265 270 Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro 275 280 285 Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 290 295 300 Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 305 310 315 320 Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala 325 330 335 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln 340 345 350 Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly 355 360 365 Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro 370 375 380 Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser 385 390 395 400 Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu 405 410 415 Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 420 425 430 Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys 435 440 <210> 622 <211> 443 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v93 IgG4-S228P.YTE des-K heavy chain <400> 622 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Ile Phe Arg Ser Tyr 20 25 30 Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Thr Ile Asn Ser Gly Gly Thr Arg Thr Tyr Tyr Pro Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Asn Ser Tyr Ser Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu 115 120 125 Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys 130 135 140 Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser 145 150 155 160 Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser 165 170 175 Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser 180 185 190 Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn 195 200 205 Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro 210 215 220 Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe 225 230 235 240 Pro Pro Lys Pro Lys Asp Thr Leu Tyr Ile Thr Arg Glu Pro Glu Val 245 250 255 Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe 260 265 270 Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro 275 280 285 Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 290 295 300 Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 305 310 315 320 Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala 325 330 335 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln 340 345 350 Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly 355 360 365 Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro 370 375 380 Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser 385 390 395 400 Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu 405 410 415 Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 420 425 430 Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly 435 440 <210> 623 <211> 219 <212> PRT <213> Artificial Sequence <220> <223> Synthetic: Hu37D3-H9.v93 IgG4-S228P.YTE light chain <400> 623 Glu Asp Leu Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Gln Ser Ile Val His Ser 20 25 30 Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Gln Gln Lys Pro Gly Lys Ser 35 40 45 Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile 65 70 75 80 Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly 85 90 95 Thr Leu Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 115 120 125 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 130 135 140 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 145 150 155 160 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 165 170 175 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 180 185 190 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 195 200 205 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 624 <211> twenty three <212> PRT <213> Artificial Sequence <220> <223> Synthetic: N-terminally biotinylated peptide <400> 624 Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly Thr 1 5 10 15 Tyr Gly Leu Gly Asp Arg Lys 20 [Brief explanation of the drawings]

[0032] [Figure 1A] Binding of antibodies to hyperphosphorylated Tau (pTau) was compared to non-phosphorylated Tau using ELISA. Results are expressed as optical density (OD). [Figure 1B] Binding of antibodies to hyperphosphorylated Tau (pTau) was compared to non-phosphorylated Tau using ELISA. Results are expressed as optical density (OD). [Figure 1C] Binding of antibodies to hyperphosphorylated Tau (pTau) was compared to non-phosphorylated Tau using ELISA. Results are expressed as optical density (OD). [Figure 1D] Binding of antibodies to hyperphosphorylated Tau (pTau) was compared to non-phosphorylated Tau using ELISA. Results are expressed as optical density (OD). [Figure 1E] Binding of antibodies to hyperphosphorylated Tau (pTau) was compared to non-phosphorylated Tau using ELISA. Results are expressed as optical density (OD). [Figure 1F] Binding of antibodies to hyperphosphorylated Tau (pTau) was compared to non-phosphorylated Tau using ELISA. Results are expressed as optical density (OD). [Figure 2A] Binding of antibodies to oligomeric Tau was assessed using oligo- and mono-Tau capture ELISA. Results are expressed as optical density (OD). [Figure 2B] Binding of antibodies to oligomeric Tau was assessed using oligo- and mono-Tau capture ELISA. Results are expressed as optical density (OD). [Figure 2C] Binding of antibodies to oligomeric Tau was assessed using oligo- and mono-Tau capture ELISA. Results are expressed as optical density (OD). [Figure 2D] Binding of antibodies to oligomeric Tau was assessed using oligo- and mono-Tau capture ELISA. Results are expressed as optical density (OD). [Figure 2E] Binding of antibodies to oligomeric Tau was assessed using oligo- and mono-Tau capture ELISA. Results are expressed as optical density (OD). [Figure 3]The three tested panTau antibodies demonstrate binding to soluble Tau in brain lysates from Alzheimer's disease (AD) and matched control donors using Western blot (WB) assays. Protein extracts from AD and control brain lysates, as well as six isoforms of recombinant human Tau, were...

Claims

1. 1. An isolated antibody that binds to human Tau, comprising: a) HVR-H1 comprises the amino acid sequence of SEQ ID NO: 342, HVR-H2 comprises the amino acid sequence of SEQ ID NO: 343, HVR-H3 comprises the amino acid sequence of SEQ ID NO: 344, HVR-L1 comprises the amino acid sequence of SEQ ID NO: 608, HVR-L2 comprises the amino acid sequence of SEQ ID NO: 609, and HVR-L3 comprises the amino acid sequence of SEQ ID NO: 610, or b) An isolated antibody, wherein HVR-H1 comprises the amino acid sequence of SEQ ID NO:605, HVR-H2 comprises the amino acid sequence of SEQ ID NO:606, HVR-H3 comprises the amino acid sequence of SEQ ID NO:607, HVR-L1 comprises the amino acid sequence of SEQ ID NO:345, HVR-L2 comprises the amino acid sequence of SEQ ID NO:346, and HVR-L3 comprises the amino acid sequence of SEQ ID NO:

347.

2. 2. The isolated antibody of claim 1, wherein the antibody binds to monomeric Tau, oligomeric Tau, non-phosphorylated Tau, and phosphorylated Tau.

3. 3. The isolated antibody of claim 1 or claim 2, which binds to an epitope within amino acids 2-24 of mature human Tau.

4. The isolated antibody of any one of claims 1 to 3, which is a monoclonal antibody.

5. The isolated antibody of any one of claims 1 to 4, which is a humanized or chimeric antibody.

6. The isolated antibody of any one of claims 1 to 5, wherein the antibody is an antibody fragment that binds to human Tau.

7. The isolated antibody of any one of claims 1 to 6, wherein the human Tau comprises the sequence of SEQ ID NO:

2.

8. a) a heavy chain variable region (VH) comprising a sequence at least 95% identical to SEQ ID NO: 340; b) a light chain variable region (VL) comprising a sequence at least 95% identical to SEQ ID NO: 604; c) a VH comprising a sequence at least 95% identical to SEQ ID NO: 340 and a VL comprising a sequence at least 95% identical to SEQ ID NO: 604; d) a heavy chain variable region (VH) comprising a sequence at least 95% identical to SEQ ID NO: 340; e) a light chain variable region (VL) comprising a sequence at least 95% identical to SEQ ID NO:615; f) a VH comprising a sequence at least 95% identical to SEQ ID NO: 340 and a VL comprising a sequence at least 95% identical to SEQ ID NO: 615; g) a heavy chain variable region (VH) comprising a sequence at least 95% identical to SEQ ID NO: 340; h) a light chain variable region (VL) comprising a sequence at least 95% identical to SEQ ID NO: 620; i) a VH comprising a sequence at least 95% identical to SEQ ID NO: 340 and a VL comprising a sequence at least 95% identical to SEQ ID NO: 620; j) a heavy chain variable region (VH) comprising a sequence at least 95% identical to SEQ ID NO: 603; k) a light chain variable region (VL) comprising a sequence at least 95% identical to SEQ ID NO: 341; l) a VH comprising a sequence at least 95% identical to SEQ ID NO: 603 and a VL comprising a sequence at least 95% identical to SEQ ID NO: 341; m) a heavy chain variable region (VH) comprising a sequence at least 95% identical to SEQ ID NO: 614; n) a light chain variable region (VL) comprising a sequence at least 95% identical to SEQ ID NO: 341; o) a VH comprising a sequence at least 95% identical to SEQ ID NO: 614 and a VL comprising a sequence at least 95% identical to SEQ ID NO: 341; p) a heavy chain variable region (VH) comprising a sequence at least 95% identical to SEQ ID NO: 619; q) a light chain variable region (VL) comprising a sequence at least 95% identical to SEQ ID NO: 341; or r) a VH comprising a sequence at least 95% identical to SEQ ID NO: 619 and a VL comprising a sequence at least 95% identical to SEQ ID NO: 341 The isolated antibody of any one of claims 1 to 7, comprising:

9. a) a heavy chain variable region (VH) comprising the sequence of SEQ ID NO: 340; b) a light chain variable region (VL) comprising the sequence of SEQ ID NO: 604; c) a light chain variable region (VL) comprising the sequence of SEQ ID NO: 615; d) a light chain variable region (VL) comprising the sequence of SEQ ID NO: 620; e) a heavy chain variable region (VH) comprising the sequence of SEQ ID NO: 603; f) a light chain variable region (VL) comprising the sequence of SEQ ID NO: 341; g) a heavy chain variable region (VH) comprising the sequence of SEQ ID NO: 614; or h) a heavy chain variable region (VH) comprising the sequence of SEQ ID NO: 619; The isolated antibody of any one of claims 1 to 7, comprising:

10. The isolated antibody of any one of claims 1 to 9, which is an IgG1 or IgG4 antibody.

11. The isolated antibody of claim 10 which is an IgG4 antibody.

12. 12. The isolated antibody of claim 11, comprising M252Y, S254T, and T256E mutations.

13. 13. The isolated antibody of claim 11 or claim 12, comprising an S228P mutation.

14. K of less than 100 nM, less than 75 nM, less than 50 nM, less than 10 nM, less than 5 nM, or less than 1 nM for each of monomeric Tau, phosphorylated Tau, non-phosphorylated Tau, and oligomeric Tau. D The isolated antibody of any one of claims 1 to 13, which binds at

15. K<1 nM for human monomeric Tau D The isolated antibody of any one of claims 1 to 14, which binds at

16. K D 16. The isolated antibody of claim 14 or claim 15, wherein the antibody has a specific binding affinity to the antibody, as determined by surface plasmon resonance at 37°C.

17. The isolated antibody of any one of claims 1 to 16, which binds to cynomolgus monkey Tau.

18. An isolated nucleic acid encoding the antibody of any one of claims 1 to 17.

19. A host cell comprising the nucleic acid of claim 18.

20. 20. A method for producing an antibody comprising culturing a host cell according to claim 19 under conditions suitable for the production of the antibody.

21. 18. An immunoconjugate comprising the isolated antibody of any one of claims 1 to 17 and a second therapeutic agent.

22. A labeled antibody comprising the antibody of any one of claims 1 to 17 and a detectable label.

23. A pharmaceutical composition comprising the isolated antibody of any one of claims 1 to 17 and a pharma- ceutically acceptable carrier.

24. A medicament for treating a Tau protein-related disease, comprising the isolated antibody according to any one of claims 1 to 17, or the pharmaceutical composition according to claim 23.

25. The pharmaceutical composition according to claim 24, wherein the Tau protein-related disease is a tauopathy.

26. The pharmaceutical composition according to claim 25, wherein the tauopathy is a neurodegenerative tauopathy.

27. Tauopathies include Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, Creutzfeldt-Jakob disease, punch-drunk syndrome, Down's syndrome, Gerstmann-Sträussler-Scheinker disease, inclusion body myositis, prion protein cerebral amyloid angiopathy, traumatic brain injury, Guam amyotrophic lateral sclerosis / Parkinsonism dementia syndrome, non-Guam motor neuron disease with neurofibrillary tangles, argyrophilic grain dementia, corticobasal degeneration, diffuse neurofibrillary tangle disease with calcifications, frontotemporal dementia, frontotemporal dementia linked to chromosome 17 and Parkinson's syndrome, Hallervorden-Spatz disease, and The pharmaceutical agent according to claim 25 or 26, which is selected from the group consisting of multiple system atrophy, Niemann-Pick disease type C, pallido-ponto-nigra degeneration, Pick's disease, progressive subcortical gliosis, progressive supranuclear palsy, subacute sclerosing panencephalitis, neurofibrillary tangle dementia, postencephalitic parkinsonism, and myotonic dystrophy.

28. The pharmaceutical agent according to any one of claims 25 to 27, wherein the tauopathy is Alzheimer's disease or progressive supranuclear palsy.

29. A medicament for preserving or increasing cognitive memory capacity or slowing memory loss in an individual, comprising an isolated antibody according to any one of claims 1 to 17, or a pharmaceutical composition according to claim 23.

30. A medicament for reducing the level of Tau protein, non-phosphorylated Tau protein, phosphorylated Tau protein or hyperphosphorylated Tau protein in an individual, comprising an isolated antibody according to any one of claims 1 to 17 or a pharmaceutical composition according to claim 23.

31. The medicament according to any one of claims 24 to 30, further comprising at least one additional therapeutic agent.

32. 32. The pharmaceutical composition of claim 31, wherein the additional therapeutic agent is selected from neurological agents, corticosteroids, antibiotics, antiviral agents, anti-Tau antibodies, Tau inhibitors, anti-amyloid beta antibodies, beta-amyloid aggregation inhibitors, anti-BACE1 antibodies, BACE1 inhibitors, cholinesterase inhibitors (ChEI), NMDA receptor antagonists, and nutritional supplements.

33. 33. The method of claim 32, wherein the ChEI is tacrine, rivastigmine, donepezil, or galantamine and the NMDA receptor antagonist is memantine.

34. The pharmaceutical composition of claim 32, wherein the anti-amyloid beta antibody is crenezumab.

35. 18. An isolated antibody according to any one of claims 1 to 17 for use as a medicament.

36. 18. The isolated antibody of any one of claims 1 to 17 for use in treating a tauopathy in an individual.

37. 37. The isolated antibody of claim 36, wherein the tauopathy is a neurodegenerative tauopathy.

38. Tauopathies include Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, Creutzfeldt-Jakob disease, punch-drunk syndrome, Down's syndrome, Gerstmann-Sträussler-Scheinker disease, inclusion body myositis, prion protein cerebral amyloid angiopathy, traumatic brain injury, Guam amyotrophic lateral sclerosis / Parkinsonism dementia syndrome, non-Guam motor neuron disease with neurofibrillary tangles, argyrophilic grain dementia, corticobasal degeneration, diffuse glaucoma with calcifications, and glaucoma.

38. The isolated antibody of claim 36 or claim 37, wherein the antibody is selected from cancer-related neurofibrillary tangle disease, frontotemporal dementia, frontotemporal dementia with parkinsonism linked to chromosome 17, Hallervorden-Spatz disease, multiple system atrophy, Niemann-Pick disease type C, pallido-pontocephalic-nigral degeneration, Pick's disease, progressive subcortical gliosis, progressive supranuclear palsy, subacute sclerosing panencephalitis, neurofibrillary tangle dementia, postencephalitic parkinsonism, and myotonic dystrophy.

39. The isolated antibody of any one of claims 36 to 38, wherein the tauopathy is Alzheimer's disease or progressive supranuclear palsy.

40. 20. The isolated antibody of any one of claims 1 to 17 for use in preserving or increasing cognitive memory capacity, or slowing memory loss, in an individual.

41. 18. The isolated antibody of any one of claims 1 to 17 for use in reducing the level of Tau protein, phosphorylated Tau protein, non-phosphorylated Tau protein or hyperphosphorylated Tau protein in an individual.

42. The isolated antibody of any one of claims 36 to 41, for use in conjunction with at least one additional therapy.

43. 43. The isolated antibody of claim 42, wherein the additional therapy is selected from a neurological agent, a corticosteroid, an antibiotic, an antiviral agent, an anti-Tau antibody, an anti-amyloid beta antibody, an anti-BACE1 antibody, a BACE1 inhibitor, a cholinesterase inhibitor (ChEI), an NMDA receptor antagonist, and a nutritional supplement.

44. 44. The isolated antibody of claim 43, wherein the ChEI is tacrine, rivastigmine, donepezil, or galantamine and the NMDA receptor antagonist is memantine.

45. 44. The isolated antibody of claim 43, wherein the anti-amyloid beta antibody is crenezumab.

46. 20. Use of an isolated antibody according to any one of claims 1 to 17 for the manufacture of a medicament for the treatment of a Tau protein-related disease in an individual.

47. 47. The use according to claim 46, wherein the Tau protein-related disease is a tauopathy.

48. 48. The use according to claim 47, wherein the tauopathy is a neurodegenerative tauopathy.

49. Tauopathies include Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, Creutzfeldt-Jakob disease, pulmonary pleural effusion syndrome, Down's syndrome, Gerstmann-Sträussler-Scheinker disease, inclusion body myositis, prion protein cerebral amyloid angiopathy, traumatic brain injury, Guam amyotrophic lateral sclerosis / Parkinsonism dementia syndrome, non-Guam motor neuron disease with neurofibrillary tangles, argyrophilic grain dementia, corticobasal degeneration, and calcification-associated tauopathy.

49. The use according to claim 47 or claim 48, wherein the disease is selected from diffuse neurofibrillary tangle disease, frontotemporal dementia, frontotemporal dementia with parkinsonism linked to chromosome 17, Hallervorden-Spatz disease, multiple system atrophy, Niemann-Pick disease type C, pallido-pontocephalic-nigral degeneration, Pick's disease, progressive subcortical gliosis, progressive supranuclear palsy, subacute sclerosing panencephalitis, neurofibrillary tangle dementia, postencephalitic parkinsonism, and myotonic dystrophy.

50. The use according to any one of claims 47 to 49, wherein the tauopathy is Alzheimer's disease or progressive supranuclear palsy.

51. 20. Use of an isolated antibody according to any one of claims 1 to 17 for the manufacture of a medicament for the preservation or increase of cognitive memory capacity, or slowing of memory loss in an individual.

52. The use according to any one of claims 46 to 51, wherein the medicament is for administration in combination with at least one additional therapy.

53. 53. The use of claim 52, wherein the additional therapy is selected from neurological agents, corticosteroids, antibiotics, antiviral agents, anti-Tau antibodies, anti-amyloid beta antibodies, anti-BACE1 antibodies, BACE1 inhibitors, cholinesterase inhibitors (ChEI), NMDA receptor antagonists, and nutritional supplements.

54. 54. The use of claim 53, wherein the ChEI is tacrine, rivastigmine, donepezil, or galantamine and the NMDA receptor antagonist is memantine.

55. 54. The use of claim 53, wherein the anti-amyloid beta antibody is crenezumab.

56. A method for detecting neurofibrillary tangles, neuropil threads, or degenerated neurites, comprising contacting an isolated biological sample with an isolated antibody according to any one of claims 1 to 17.

57. 57. The method of claim 56, wherein the isolated biological sample is a brain sample, a cerebrospinal fluid sample, or a blood sample.

Citation Information

Patent Citations

  • Treatment methods for tauopathy

    JP2015532592A

  • How to treat tauopathy

    JP2016525502A

  • Anti-TAU antibodies and methods of use

    JP2020511938A

  • JPP7193457B